Form 10-Q
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
|
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
|
|
|
þ |
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended May 31, 2008
or
|
|
|
o |
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from _________ to _________
Commission file number 001-16167
MONSANTO COMPANY
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
(State or other jurisdiction of incorporation or organization)
|
|
43-1878297
(I.R.S. Employer Identification No.) |
|
|
|
800 North Lindbergh Blvd.,
St. Louis, MO
(Address of principal executive offices)
|
|
63167
(Zip Code) |
(314) 694-1000
(Registrants telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed
by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes þ No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):
|
|
|
|
|
|
|
Large accelerated filer þ
|
|
Accelerated filer o
|
|
Non-accelerated filer o
|
|
Smaller reporting company o |
|
|
(Do not check if a smaller reporting company) |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of
the Exchange Act). Yes o No þ
Indicate the number of shares outstanding of each of the issuers classes of common stock, as
of the latest practicable date: 550,001,886 shares of Common Stock, $0.01 par value, outstanding as
of June 24, 2008.
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
In the interests of our investors, and in accordance with the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995, this section of our report explains some of the
important reasons that actual results may be materially different from those that we anticipate. In
this report, and from time to time throughout the year, we share our expectations for our companys
future performance. These forward-looking statements include statements about our business plans;
the potential development, regulatory approval, and public acceptance of our products; our expected
financial performance, including sales performance, and the anticipated effect of our strategic
actions; the anticipated benefits of recent acquisitions; the outcome of contingencies, such as
litigation; domestic or international economic, political and market conditions; and other factors
that could affect our future results of operations or financial position, including, without
limitation, statements under the captions Overview Executive Summary Outlook, Seeds and
Genomics Segment, Agricultural Productivity Segment, Financial Condition, Liquidity, and
Capital Resources, Outlook, Critical Accounting Policies and Estimates and Legal
Proceedings. Any statements we make that are not matters of current reportage or historical fact
should be considered forward-looking. Such statements often include words such as believe,
expect, anticipate, intend, plan, estimate, will, and similar expressions. By their
nature, these types of statements are uncertain and are not guarantees of our future performance.
Since these statements are based on factors that involve risks and uncertainties, our companys
actual performance and results may differ materially from those described or implied by such
forward-looking statements. Factors that could cause or contribute to such differences include,
among others: continued competition in seeds, traits and agricultural chemicals; the companys
exposure to various contingencies, including those related to intellectual property protection,
regulatory compliance and the speed with which approvals are received, and public acceptance of
biotechnology products; the success of the companys research and development activities; the
outcomes of major lawsuits; developments related to foreign currencies and economies; successful
operation of recent acquisitions; fluctuations in commodity prices; compliance with regulations
affecting our manufacturing; the accuracy of the companys estimates related to distribution
inventory levels; the companys ability to fund its short-term financing needs and to obtain
payment for the products that it sells; the effect of weather conditions, natural disasters and
accidents on the agriculture business or the companys facilities; and other risks and factors
described or referenced in Part II Item 1A Risk Factors below, Part I Item 1A of our
Report on Form 10-K for the fiscal year ended Aug. 31, 2007, and Part II Item 1A of our Report
on Form 10-Q for the quarterly period ended Feb. 29, 2008.
Our forward-looking statements represent our estimates and expectations and are based on currently
available information at the time that we make those statements. However, circumstances change
constantly, often unpredictably, and many events beyond our control will determine whether the
expectations encompassed in our forward-looking statements will be realized. As a result, investors
should not place undue reliance on these forward-looking statements. We disclaim any intention or
obligation to revise or update any forward-looking statements, or the factors that may affect their
realization, whether in light of new information, future events or otherwise, and investors should
not rely on us to do so.
1
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
TABLE OF CONTENTS
|
|
|
|
|
|
|
|
|
|
|
Page |
|
PART IFINANCIAL INFORMATION |
|
|
|
|
|
Item 1. |
|
Financial Statements |
|
|
3 |
|
|
|
Statements of Consolidated Operations |
|
|
4 |
|
|
|
Condensed Statements of Consolidated Financial Position |
|
|
5 |
|
|
|
Statements of Consolidated Cash Flows |
|
|
6 |
|
|
|
Notes to Consolidated Financial Statements |
|
|
7 |
|
Item 2. |
|
Managements Discussion and Analysis of Financial Condition and Results of Operations |
|
|
24 |
|
|
|
Overview |
|
|
24 |
|
|
|
Results of Operations Third Quarter Fiscal Year 2008 |
|
|
26 |
|
|
|
Seeds and Genomics Segment |
|
|
29 |
|
|
|
Agricultural Productivity Segment |
|
|
31 |
|
|
|
Financial Condition, Liquidity, and Capital Resources |
|
|
32 |
|
|
|
Outlook |
|
|
36 |
|
|
|
Critical Accounting Policies and Estimates |
|
|
38 |
|
|
|
New Accounting Standards |
|
|
39 |
|
Item 3. |
|
Quantitative and Qualitative Disclosures About Market Risk |
|
|
40 |
|
Item 4. |
|
Controls and Procedures |
|
|
40 |
|
|
|
|
|
|
|
|
PART IIOTHER INFORMATION |
|
|
|
|
|
Item 1. |
|
Legal Proceedings |
|
|
40 |
|
Item 1A. |
|
Risk Factors |
|
|
43 |
|
Item 2. |
|
Unregistered Sales of Equity Securities and Use of Proceeds |
|
|
43 |
|
Item 6. |
|
Exhibits |
|
|
44 |
|
SIGNATURE |
|
|
45 |
|
EXHIBIT INDEX |
|
|
46 |
|
2
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
PART IFINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
The Statements of Consolidated Operations of Monsanto Company and its consolidated subsidiaries for
the three months and nine months ended May 31, 2008, and May 31, 2007, the Condensed Statements of
Consolidated Financial Position as of May 31, 2008, and Aug. 31, 2007, the Statements of
Consolidated Cash Flows for the nine months ended May 31, 2008, and May 31, 2007, and related Notes
to Consolidated Financial Statements follow. Unless otherwise indicated, Monsanto and the
company are used interchangeably to refer to Monsanto Company or to Monsanto Company and its
consolidated subsidiaries, as appropriate to the context. Unless otherwise indicated, earnings
(loss) per share and per share mean diluted earnings (loss) per share. In the notes to the
consolidated financial statements, all dollars are expressed in millions, except per share amounts.
Unless otherwise indicated, trademarks owned or licensed by Monsanto or its subsidiaries are shown
in all capital letters. Unless otherwise indicated, references to ROUNDUP herbicides mean ROUNDUP
branded herbicides, excluding all lawn-and-garden herbicides, and references to ROUNDUP and other
glyphosate-based herbicides exclude all lawn-and-garden herbicides.
3
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
Statements of Consolidated Operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unaudited |
|
Three Months Ended May 31, |
|
|
Nine Months Ended May 31, |
|
(Dollars in millions, except per share amounts) |
|
2008 |
|
|
2007 |
|
|
2008 |
|
|
2007 |
|
|
|
|
|
Net Sales |
|
$ |
3,588 |
|
|
$ |
2,842 |
|
|
$ |
9,466 |
|
|
$ |
6,990 |
|
Cost of goods sold |
|
|
1,619 |
|
|
|
1,339 |
|
|
|
4,213 |
|
|
|
3,357 |
|
|
|
|
Gross Profit |
|
|
1,969 |
|
|
|
1,503 |
|
|
|
5,253 |
|
|
|
3,633 |
|
Operating Expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative expenses |
|
|
622 |
|
|
|
487 |
|
|
|
1,617 |
|
|
|
1,299 |
|
Research and development expenses |
|
|
251 |
|
|
|
190 |
|
|
|
672 |
|
|
|
554 |
|
Acquired in-process research and development (see Note 3) |
|
|
2 |
|
|
|
7 |
|
|
|
3 |
|
|
|
7 |
|
|
|
|
Total Operating Expenses |
|
|
875 |
|
|
|
684 |
|
|
|
2,292 |
|
|
|
1,860 |
|
Income from Operations |
|
|
1,094 |
|
|
|
819 |
|
|
|
2,961 |
|
|
|
1,773 |
|
Interest expense |
|
|
31 |
|
|
|
29 |
|
|
|
99 |
|
|
|
96 |
|
Interest income |
|
|
(34 |
) |
|
|
(28 |
) |
|
|
(105 |
) |
|
|
(89 |
) |
Solutia-related expenses (income) (see Note 16) |
|
|
|
|
|
|
4 |
|
|
|
(187 |
) |
|
|
23 |
|
Other (income) expense net |
|
|
(5 |
) |
|
|
8 |
|
|
|
(2 |
) |
|
|
9 |
|
|
|
|
Income from Continuing Operations Before Income Taxes and
Minority Interest |
|
|
1,102 |
|
|
|
806 |
|
|
|
3,156 |
|
|
|
1,734 |
|
Income tax provision |
|
|
285 |
|
|
|
231 |
|
|
|
947 |
|
|
|
521 |
|
Minority interest expense |
|
|
6 |
|
|
|
10 |
|
|
|
13 |
|
|
|
7 |
|
|
|
|
Income from Continuing Operations |
|
$ |
811 |
|
|
$ |
565 |
|
|
$ |
2,196 |
|
|
$ |
1,206 |
|
|
|
|
Discontinued Operations (see Note 18): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from operations of discontinued businesses |
|
|
|
|
|
|
8 |
|
|
|
|
|
|
|
(5 |
) |
Income tax expense (benefit) |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
(2 |
) |
|
|
|
Income (Loss) on Discontinued Operations |
|
|
|
|
|
|
5 |
|
|
|
|
|
|
|
(3 |
) |
|
|
|
Net Income |
|
$ |
811 |
|
|
$ |
570 |
|
|
$ |
2,196 |
|
|
$ |
1,203 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic Earnings (Loss) per Share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations |
|
$ |
1.48 |
|
|
$ |
1.04 |
|
|
$ |
4.01 |
|
|
$ |
2.22 |
|
Income (loss) on discontinued operations |
|
|
|
|
|
|
0.01 |
|
|
|
|
|
|
|
(0.01 |
) |
|
|
|
Net Income |
|
$ |
1.48 |
|
|
$ |
1.05 |
|
|
$ |
4.01 |
|
|
$ |
2.21 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted Earnings (Loss) per Share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations |
|
$ |
1.45 |
|
|
$ |
1.02 |
|
|
$ |
3.93 |
|
|
$ |
2.18 |
|
Income (loss) on discontinued operations |
|
|
|
|
|
|
0.01 |
|
|
|
|
|
|
|
(0.01 |
) |
|
|
|
Net Income |
|
$ |
1.45 |
|
|
$ |
1.03 |
|
|
$ |
3.93 |
|
|
$ |
2.17 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average Shares Outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
549.0 |
|
|
|
544.4 |
|
|
|
547.6 |
|
|
|
543.7 |
|
Diluted |
|
|
560.0 |
|
|
|
555.2 |
|
|
|
558.9 |
|
|
|
554.4 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dividends Declared per Share |
|
$ |
|
|
|
$ |
|
|
|
$ |
0.35 |
|
|
$ |
0.25 |
|
The accompanying notes are an integral part of these consolidated financial statements.
4
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
Condensed Statements of Consolidated Financial Position
|
|
|
|
|
|
|
|
|
|
Unaudited |
|
As of May 31, |
|
|
As of Aug. 31, |
|
(Dollars in millions, except share amounts) |
|
2008 |
|
|
2007 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets |
|
|
|
|
|
|
|
|
Current Assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
1,714 |
|
|
$ |
866 |
|
Trade receivables net of allowances of $253 and $217, respectively |
|
|
3,258 |
|
|
|
1,499 |
|
Miscellaneous receivables |
|
|
468 |
|
|
|
407 |
|
Deferred tax assets |
|
|
340 |
|
|
|
449 |
|
Inventories (see Note 5) |
|
|
2,206 |
|
|
|
1,719 |
|
Other current assets |
|
|
141 |
|
|
|
144 |
|
|
|
|
Total Current Assets |
|
|
8,127 |
|
|
|
5,084 |
|
Property, Plant and Equipment Net of Accumulated Depreciation of $3,625 and $3,260, respectively |
|
|
2,962 |
|
|
|
2,656 |
|
Goodwill (see Note 6) |
|
|
2,769 |
|
|
|
2,625 |
|
Other Intangible Assets Net (see Note 6) |
|
|
1,375 |
|
|
|
1,415 |
|
Noncurrent Deferred Tax Assets |
|
|
816 |
|
|
|
730 |
|
Long-Term Receivables Net of Allowances of $172 and $131, respectively |
|
|
653 |
|
|
|
79 |
|
Other Assets |
|
|
590 |
|
|
|
394 |
|
|
|
|
Total Assets |
|
$ |
17,292 |
|
|
$ |
12,983 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities and Shareowners Equity |
|
|
|
|
|
|
|
|
Current Liabilities: |
|
|
|
|
|
|
|
|
Short-term debt, including current portion of long-term debt |
|
$ |
10 |
|
|
$ |
270 |
|
Accounts payable |
|
|
788 |
|
|
|
649 |
|
Income taxes payable |
|
|
134 |
|
|
|
150 |
|
Accrued compensation and benefits |
|
|
368 |
|
|
|
349 |
|
Accrued marketing programs |
|
|
720 |
|
|
|
517 |
|
Deferred revenues |
|
|
369 |
|
|
|
260 |
|
Grower production accruals |
|
|
120 |
|
|
|
86 |
|
Dividends payable |
|
|
|
|
|
|
96 |
|
Miscellaneous short-term accruals |
|
|
779 |
|
|
|
698 |
|
|
|
|
Total Current Liabilities |
|
|
3,288 |
|
|
|
3,075 |
|
Long-Term Debt |
|
|
1,703 |
|
|
|
1,150 |
|
Postretirement Liabilities |
|
|
505 |
|
|
|
542 |
|
Long-Term Portion of Environmental and Related Litigation Reserve (see Note 16) |
|
|
150 |
|
|
|
135 |
|
Long-Term Deferred Revenue |
|
|
588 |
|
|
|
|
|
Other Liabilities |
|
|
847 |
|
|
|
578 |
|
Commitments and Contingencies (see Note 16) |
|
|
|
|
|
|
|
|
Shareowners Equity: |
|
|
|
|
|
|
|
|
Common stock (authorized: 1,500,000,000 shares, par value $0.01)
Issued 582,675,829 and 577,244,601 shares, respectively;
Outstanding 549,616,457 and 545,609,310 shares, respectively |
|
|
6 |
|
|
|
6 |
|
Treasury stock, 33,059,372 and 31,635,291 shares, respectively, at cost |
|
|
(961 |
) |
|
|
(814 |
) |
Additional contributed capital |
|
|
9,428 |
|
|
|
9,106 |
|
Retained earnings (deficit) (includes cumulative effect of adopting FIN 48 as of Sept. 1, 2007, of ($25)) |
|
|
1,574 |
|
|
|
(405 |
) |
Accumulated other comprehensive income (loss) |
|
|
174 |
|
|
|
(377 |
) |
Reserve for ESOP debt retirement |
|
|
(10 |
) |
|
|
(13 |
) |
|
|
|
Total Shareowners Equity |
|
|
10,211 |
|
|
|
7,503 |
|
|
|
|
Total Liabilities and Shareowners Equity |
|
$ |
17,292 |
|
|
$ |
12,983 |
|
|
|
|
The accompanying notes are an integral part of these consolidated financial statements.
5
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
Statements of Consolidated Cash Flows
|
|
|
|
|
|
|
|
|
|
Unaudited |
|
Nine Months Ended May 31, |
|
(Dollars in millions) |
|
2008 |
|
|
2007 |
|
|
|
|
|
|
|
|
|
|
|
Operating Activities: |
|
|
|
|
|
|
|
|
Net Income |
|
$ |
2,196 |
|
|
$ |
1,203 |
|
Adjustments to reconcile cash provided by operating activities: |
|
|
|
|
|
|
|
|
Items that did not require (provide) cash: |
|
|
|
|
|
|
|
|
Depreciation and amortization expense |
|
|
423 |
|
|
|
386 |
|
Bad-debt expense |
|
|
52 |
|
|
|
29 |
|
Receipt of securities from Solutia settlement (see Notes 7 and 16) |
|
|
(38 |
) |
|
|
|
|
Stock-based compensation expense |
|
|
64 |
|
|
|
54 |
|
Excess tax benefits from stock-based compensation |
|
|
(161 |
) |
|
|
(49 |
) |
Deferred income taxes |
|
|
126 |
|
|
|
(10 |
) |
Equity affiliate expense net |
|
|
2 |
|
|
|
30 |
|
Acquired in-process research and development (see Note 3) |
|
|
3 |
|
|
|
7 |
|
Other items |
|
|
(10 |
) |
|
|
(1 |
) |
Changes in assets and liabilities that provided (required) cash, net of acquisitions: |
|
|
|
|
|
|
|
|
Trade receivables |
|
|
(1,490 |
) |
|
|
(1,969 |
) |
Inventories |
|
|
(387 |
) |
|
|
91 |
|
Deferred revenues |
|
|
(1 |
) |
|
|
(45 |
) |
Accounts payable and other accrued liabilities |
|
|
746 |
|
|
|
466 |
|
Net investment hedge settlement |
|
|
(97 |
) |
|
|
(4 |
) |
Other items |
|
|
(103 |
) |
|
|
(99 |
) |
|
Net Cash Provided by Operating Activities |
|
|
1,325 |
|
|
|
89 |
|
|
Cash Flows Provided (Required) by Investing Activities: |
|
|
|
|
|
|
|
|
Maturities of short-term investments |
|
|
59 |
|
|
|
22 |
|
Capital expenditures |
|
|
(530 |
) |
|
|
(297 |
) |
Acquisitions of businesses, net of cash acquired |
|
|
(113 |
) |
|
|
(125 |
) |
Purchases of long-term equity securities |
|
|
(78 |
) |
|
|
|
|
Technology and other investments |
|
|
(39 |
) |
|
|
(35 |
) |
Other investments and property disposal proceeds |
|
|
51 |
|
|
|
25 |
|
|
Net Cash Required by Investing Activities |
|
|
(650 |
) |
|
|
(410 |
) |
|
Cash Flows Provided (Required) by Financing Activities: |
|
|
|
|
|
|
|
|
Net change in financing with less than 90-day maturities |
|
|
(28 |
) |
|
|
265 |
|
Short-term debt reductions |
|
|
(9 |
) |
|
|
(8 |
) |
Long-term debt proceeds |
|
|
548 |
|
|
|
4 |
|
Long-term debt reductions |
|
|
(238 |
) |
|
|
(277 |
) |
Payments on other financing |
|
|
(3 |
) |
|
|
(4 |
) |
Debt issuance costs |
|
|
(5 |
) |
|
|
|
|
Treasury stock purchases |
|
|
(145 |
) |
|
|
(101 |
) |
Stock option exercises |
|
|
100 |
|
|
|
59 |
|
Excess tax benefits from stock-based compensation |
|
|
161 |
|
|
|
49 |
|
Dividend payments |
|
|
(288 |
) |
|
|
(191 |
) |
|
Net Cash Provided (Required) by Financing Activities |
|
|
93 |
|
|
|
(204 |
) |
|
Effect of Exchange Rate Changes on Cash and Cash Equivalents |
|
|
80 |
|
|
|
59 |
|
|
Net Increase (Decrease) in Cash and Cash Equivalents |
|
|
848 |
|
|
|
(466 |
) |
Cash and Cash Equivalents at Beginning of Period |
|
|
866 |
|
|
|
1,460 |
|
|
Cash and Cash Equivalents at End of Period |
|
$ |
1,714 |
|
|
$ |
994 |
|
|
See Note 15 Supplemental Cash Flow Information for further details.
The accompanying notes are an integral part of these consolidated financial statements.
6
|
|
|
MONSANTO COMPANY |
|
THIRD QUARTER 2008 FORM 10-Q |
|
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED
NOTE 1. BACKGROUND AND BASIS OF PRESENTATION
Monsanto Company, along with its subsidiaries, is a leading global provider of agricultural
products for farmers. Monsantos seeds, biotechnology trait products, and herbicides provide
farmers with solutions that improve productivity, reduce the costs of farming, and produce better
foods for consumers and better feed for animals.
Monsanto manages its business in two segments: Seeds and Genomics, and Agricultural Productivity.
Through the Seeds and Genomics segment, Monsanto produces leading seed brands, including DEKALB,
ASGROW, D&PL, DELTAPINE and SEMINIS, and Monsanto develops biotechnology traits that assist farmers
in controlling insects and weeds. Monsanto also provides other seed companies with genetic material
and biotechnology traits for their seed brands. Through the Agricultural Productivity segment, the
company manufactures ROUNDUP brand herbicides and other herbicides and provides lawn-and-garden
herbicide products for the residential market and animal agricultural products focused on improving
dairy cow productivity. See Note 17 Segment Information for further details.
In the
fourth quarter of 2007, the company sold its U.S. Stoneville and NexGen businesses as part of
the U.S. Department of Justice (DOJ) approval for the acquisition of Delta and Pine Land Company
(DPL). As a result, the financial data for these businesses have been presented as discontinued
operations and have been recast and prepared in compliance with the provisions of Statement of
Financial Accounting Standards (SFAS) No. 144, Accounting for the Impairment or Disposal of
Long-Lived Assets (SFAS 144). Accordingly, for all periods presented herein, the Statements of
Consolidated Operations have been conformed to this presentation. See Note 18 Discontinued
Operations for further details.
The accompanying consolidated financial statements have not been audited but have been prepared in
conformity with accounting principles generally accepted in the United States for interim financial
information and with instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of
management, these unaudited consolidated financial statements contain all adjustments necessary to
present fairly the financial position, results of operations and cash flows for the interim periods
reported. This Report on Form 10-Q should be read in conjunction with Monsantos Report on Form
10-K for the fiscal year ended Aug. 31, 2007, and Monsantos Report on Form 10-Q for the quarterly
periods ended Nov. 30, 2007, and Feb. 29, 2008. Financial information for the first nine months of
fiscal year 2008 should not be annualized because of the seasonality of the companys business.
NOTE 2. NEW ACCOUNTING STANDARDS
In May 2008, the Financial Accounting Standards Boards (FASB) issued SFAS No. 162, The Hierarchy of
Generally Accepted Accounting Principles (SFAS 162). SFAS 162 identifies the sources of accounting
principles and the framework for selecting principles to be used in the preparation and
presentation of financial statements in accordance with generally accepted accounting principles.
This statement will be effective 60 days after the Securities and Exchange Commission approves the
Public Company Accounting Oversight Boards amendments to AU Section 411, The Meaning of Present
Fairly in Conformity With Generally Accepted Accounting Principles. Monsanto does not anticipate
the adoption of SFAS 162 will have an effect on the consolidated financial statements.
In March 2008, the FASB issued SFAS No. 161, Disclosures about Derivative Instruments and Hedging
Activities (SFAS 161). SFAS 161 amends and expands the disclosure requirements of SFAS 133,
Accounting for Derivative Instruments and Hedging Activities (SFAS 133). It requires qualitative
disclosures about objectives and strategies for using derivatives, quantitative disclosures about
fair value amounts of gains and losses on derivative instruments, and disclosures about
credit-risk-related contingent features in derivative agreements. This statement is effective for
financial statements issued for fiscal periods beginning after Nov. 15, 2008. Accordingly, Monsanto will adopt SFAS 161 in second quarter
2009. The company is currently evaluating the impact of SFAS 161 on the consolidated financial
statements.
In December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests in Consolidated Financial
Statements an amendment of ARB No. 51 (SFAS 160). SFAS 160 requires an entity to clearly
identify and present ownership interests in
7
|
|
|
MONSANTO COMPANY |
|
THIRD QUARTER 2008 FORM 10-Q |
|
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED (continued)
subsidiaries held by parties other than the entity in the consolidated financial statements within
the equity section but separate from the entitys equity. It also requires the amount of
consolidated net income attributable to the parent and to the noncontrolling interest be clearly
identified and presented on the face of the consolidated statement of income; changes in ownership
interest be accounted for similarly, as equity transactions; and when a subsidiary is
deconsolidated, any retained noncontrolling equity investment in the former subsidiary and the gain
or loss on the deconsolidation of the subsidiary be measured at fair value. This statement is
effective for financial statements issued for fiscal years beginning after Dec. 15, 2008.
Accordingly, Monsanto will adopt SFAS 160 in fiscal year 2010. The company is currently evaluating
the impact of SFAS 160 on the consolidated financial statements.
In December 2007, the FASB issued SFAS No. 141 (revised 2007), Business Combinations (SFAS 141R).
Under SFAS 141R, an entity is required to recognize the assets acquired, liabilities assumed,
contractual contingencies and contingent consideration measured at their fair value at the
acquisition date. It further requires that acquisition-related costs are to be recognized
separately from the acquisition and expensed as incurred. In addition, acquired in-process research
and development (IPR&D) is capitalized as an intangible asset and amortized over its estimated
useful life. The IPR&D is evaluated for impairment and if no alternative future use exists, the
asset is expensed. SFAS 141R is effective for business combinations for which the acquisition date
is after the beginning of the first annual reporting period beginning after Dec. 15, 2008.
Accordingly, Monsanto will adopt SFAS 141R in fiscal year 2010. The Company is currently evaluating the impact of SFAS 141R on the consolidated financial statements.
In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and
Financial Liabilities (SFAS 159). SFAS 159 permits entities to choose to measure many financial
instruments and certain other items at fair value. The objective is to improve financial reporting
by providing entities with the opportunity to mitigate volatility in reported earnings caused by
measuring related assets and liabilities using different measurement techniques. SFAS 159 requires
additional disclosures related to the fair value measurements included in the entitys financial
statements. This statement is effective for financial statements issued for fiscal years beginning
after Nov. 15, 2007. Accordingly, Monsanto will adopt SFAS 159 in fiscal year 2009. The company is
currently evaluating the impact of SFAS 159 on the consolidated financial statements.
In September 2006, the FASB issued SFAS No. 157, Fair Value Measurements (SFAS 157). SFAS 157
defines fair value, establishes a framework for measuring fair value in generally accepted
accounting principles, and expands disclosures about fair value measurements. This statement is
effective for financial statements issued for fiscal years beginning after Nov. 15, 2007.
Accordingly, Monsanto will adopt SFAS 157 in fiscal year 2009. The company is currently evaluating
the impact of SFAS 157 on the consolidated financial statements.
NOTE 3. BUSINESS COMBINATIONS
2008 Acquisitions: In September 2007, Monsanto acquired 100 percent of the outstanding stock of
Agroeste Sementes (Agroeste), a leading Brazilian corn seed company, for approximately $90 million
(net of cash acquired and debt assumed), inclusive of transaction costs of approximately $1
million. Agroeste focuses on hybrid corn seed production and serves farmers throughout Brazil.
Monsanto consummated the transaction with cash. The financial results of this business were
included in the companys consolidated financial statements from the date of acquisition.
In fiscal
year 2008, Monsanto completed other acquisitions for approximately $16 million, inclusive of transaction costs of $1 million, and the
financial results of these businesses were included in the companys consolidated financial
statements from the respective dates of acquisition.
A charge of approximately $3 million was recorded in research and development expenses in fiscal
year 2008, for the write-off of acquired IPR&D related to 2008 acquisitions and finalizing the
purchase price allocations for 2007 acquisitions. Management believed that the technological
feasibility of the IPR&D was not established and that the research had no alternative future uses.
Accordingly, the amount allocated to IPR&D was expensed immediately, in accordance with generally
accepted accounting principles.
Proforma information related to these acquisitions is not presented because the impact of these
acquisitions on the companys consolidated results of operations is not considered to be
significant. The purchase price for these acquisitions was primarily
8
|
|
|
MONSANTO COMPANY |
|
THIRD QUARTER 2008 FORM 10-Q |
|
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED (continued)
allocated to goodwill, intangible assets, and fixed assets. The primary items that generated the goodwill were the
premiums paid by the company for the right to control the businesses acquired and the value of the
acquired assembled workforces.
2007 Acquisitions: In June 2007, Monsanto completed the purchase of all the outstanding stock of
DPL, the largest cotton seed breeder in the world, for a cash purchase price of $42 per share, or
approximately $1.5 billion (net of cash acquired and debt assumed), inclusive of transaction costs
of approximately $37 million.
In January and May 2007, Monsanto acquired two European vegetable and fruit seed companies in
separate transactions for an aggregate purchase price of $61 million, inclusive of transaction
costs of $10 million.
In December 2006, Monsantos American Seeds, Inc. (ASI) subsidiary acquired Fielders Choice
Direct, a U.S. seed company, for $50 million (net of cash acquired), inclusive of transaction costs
of $1 million. In conjunction with this acquisition, Monsanto entered into a five-year global
technology license agreement. Also, in fiscal year 2007, ASI acquired nine regional U.S. seed
companies in separate transactions for an aggregate purchase price of $37 million, inclusive of
transaction costs of $2 million. In addition, one of these ASI acquisitions included an earn-out
amount of up to $1 million, of which approximately $1 million was paid in first quarter 2008.
For all fiscal year 2008 and 2007 acquisitions described above, the business operations and
employees of the acquired entities were added into the Seeds and Genomics segment results upon
acquisition. These acquisitions were accounted for as purchase transactions. Accordingly, the
assets and liabilities of the acquired entities were recorded at their estimated fair values at the
dates of the acquisitions. The purchase price allocations for the fourth quarter 2007 acquisitions
and the fiscal year 2008 acquisitions are preliminary and are subject to adjustment pending further
assessments, including the valuation of certain assets.
As of the acquisition dates, management began to assess and formulate plans to restructure the
acquired entities. These activities are accounted for in accordance with Emerging Issues Task Force
(EITF) 95-3, Recognition of Liabilities in Connection with a Purchase Business Combination (EITF
95-3), and primarily include the potential closure of facilities, the abandonment or redeployment
of equipment, and employee terminations or relocations. Through May 31, 2008, estimated costs of
$18 million have been recognized as current liabilities in the purchase price allocations above,
and $10 million has been charged against these liabilities, primarily related to payments for
employee terminations, facility closures and related demolition and dismantling costs. As
management finalizes plans to integrate or restructure certain activities of the acquired entities,
further liabilities may be recorded as part of the purchase price allocation.
NOTE 4. CUSTOMER FINANCING PROGRAMS
Monsanto has established a revolving financing program to provide financing of up to $250 million
for selected customers in the United States through a third-party specialty lender. Under the
financing program, Monsanto originates customer loans on behalf of the lender, which is a special
purpose entity (SPE) that Monsanto consolidates, pursuant to Monsantos credit and other
underwriting guidelines approved by the lender. Under the program as amended in August 2006,
Monsanto services the loans and provides a first-loss guarantee of up to $130 million. Following
origination, the lender transfers the loans to multi-seller commercial paper conduits through a
nonconsolidated qualifying special purpose entity (QSPE). Monsanto accounts for this transaction as
a sale, in accordance with SFAS No. 140, Accounting for Transfers and Servicing of Financial Assets
and Extinguishment of Liabilities (SFAS 140).
Monsanto has no ownership interest in the lender, the QSPE, or the loans. However, because Monsanto
substantively originates the loans through the SPE (which it consolidates) and partially guarantees
and services the loans, Monsanto accounts for the program as if it were the originator of the loans
and the transferor selling the loans to the QSPE. Because QSPEs are excluded from the scope of FASB
Interpretation (FIN) No. 46 (revised December 2003), Consolidation of Variable Interest Entities
(FIN 46R), and Monsanto does not have the unilateral right to liquidate the QSPE, FIN 46R does not
have an effect on Monsantos accounting for the U.S. customer financing program.
Monsanto accounts for the guarantee in accordance with FIN No. 45, Guarantors Accounting and
Disclosure Requirements for Guarantees, Including Indirect Guarantees and Indebtedness of Others,
an interpretation of SFAS No. 5, 57 and 107, and
9
|
|
|
MONSANTO COMPANY |
|
THIRD QUARTER 2008 FORM 10-Q |
|
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED (continued)
rescission of FIN No. 34 (FIN 45), which requires that a guarantor recognize, at the inception of the guarantee, a liability for the fair value of
the guarantee obligation undertaken. Monsanto records its guarantee liability at a value that
approximates fair value (except that it does not discount credit losses because of the short-term
nature of the loans), primarily driven by expected future credit losses. Monsanto does not
recognize any servicing asset or liability because the servicing fee is considered adequate compensation for the servicing activities. Discounts on the sale of customer
loans and servicing expenses were $2 million during each of the nine month periods ended May 31, 2008, and May 31,
2007.
Proceeds from customer loans sold through the financing program totaled $3 million and $6 million
for the first nine months of fiscal years 2008 and 2007, respectively. These proceeds are included
in net cash provided by operating activities in the Statements of Consolidated Cash Flows. The loan
balance outstanding as of May 31, 2008, and Aug. 31, 2007, was $3 million and $301 million,
respectively. Loans are considered delinquent when payments are 31 days past due. If a customer
fails to pay an obligation when due, Monsanto would incur a liability to perform under the
first-loss guarantee. As of May 31, 2008, and Aug. 31, 2007, less than $1 million of loans sold
through this financing program were delinquent, and Monsanto recorded its guarantee liability at
less than $1 million, based on the companys historical collection experience with these customers
and a current assessment of credit exposure. Adverse changes in the actual loss rate would increase
the liability. If Monsanto is called upon to make payments under the first-loss guarantee, it would
have the benefit under the financing program of any amounts subsequently collected from the
customer.
Monsanto has an agreement with a lender to establish a program that originally provided financing
of up to $40 million for selected customers in Brazil. The agreement qualifies for sales treatment
under SFAS 140. Proceeds from the transfer of receivables are included in net cash provided by
operating activities in the Statements of Consolidated Cash Flows. Total funds available under the
program have increased to $172 million under subsequent amendments. Proceeds from the transfer of
receivables through the program totaled $107 million and $83 million for the first nine months of
fiscal years 2008 and 2007, respectively. Monsanto provides a guarantee of the loans in the event
of customer default. The term of the guarantee is equivalent to the term of the bank loans. The
liability for the guarantees is recorded at an amount that approximates fair value and is based on
the companys historical collection experience with customers that participate in the program and a
current assessment of credit exposure. The guarantee liability recorded by Monsanto was $5 million
and $3 million as of May 31, 2008, and Aug. 31, 2007, respectively. If performance is required
under the guarantee, Monsanto may retain amounts that are subsequently collected from customers.
The maximum potential amount of future payments under the guarantee was $68 million as of May 31,
2008. The loan balance outstanding for these programs was $68 million and $86 million as of May 31,
2008, and Aug. 31, 2007, respectively.
Monsanto also has similar agreements with banks that provide financing to its customers in Brazil
through credit programs that are subsidized by the Brazilian government. In addition, there are
similar financing programs in Europe and Argentina. All of these programs qualify for sales
treatment under SFAS 140. Accordingly, proceeds from the transfer of receivables are included in
net cash provided by operating activities in the Statements of Consolidated Cash Flows and totaled
$70 million and $81 million for the first nine months of fiscal years 2008 and 2007, respectively.
Under most of these programs, Monsanto provides a guarantee of the loans in the event of customer
default. The terms of the guarantees are equivalent to the terms of the bank loans. The liability
for the guarantees is recorded at an amount that approximates fair value and is based on the
companys historical collection experience with customers that participate in the program and a
current assessment of credit exposure. The guarantee liability recorded by Monsanto was $4 million
and $2 million as of May 31, 2008, and Aug. 31, 2007, respectively. If performance is required
under the guarantee, Monsanto may retain amounts that are subsequently collected from customers.
The maximum potential amount of future payments under the guarantees was $66 million as of May 31,
2008. The loan balance outstanding for these programs was $66 million as of May 31, 2008, and Aug.
31, 2007.
Monsanto also sells accounts receivable, both with and without recourse. These sales qualify for
sales treatment under SFAS 140 and accordingly, the proceeds are included in net cash provided by
operating activities in the Statements of Consolidated Cash Flows. The gross amounts of receivables
sold totaled $19 million for the first nine months of fiscal years 2008 and 2007. The liability for
the guarantees for sales with recourse is recorded at an amount that approximates fair value and is
based on the companys historical collection experience for the customers associated with the sale
of the receivables and a current assessment of credit exposure. The liability recorded by Monsanto
was less than $1 million as of May 31, 2008, and Aug. 31, 2007. The maximum potential amount of
future payments under the recourse provisions of the agreements was
10
|
|
|
MONSANTO COMPANY |
|
THIRD QUARTER 2008 FORM 10-Q |
|
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED (continued)
$16 million as of May 31, 2008. The outstanding balance of the receivables sold was $16 million and $28 million as of May 31, 2008,
and Aug. 31, 2007, respectively.
Components of inventories were:
|
|
|
|
|
|
|
|
|
|
|
As of May 31, |
|
|
As of Aug. 31, |
|
(Dollars in millions) |
|
2008 |
|
|
2007 |
|
Finished Goods |
|
$ |
953 |
|
|
$ |
635 |
|
Goods In Process |
|
|
1,077 |
|
|
|
893 |
|
Raw Materials and Supplies |
|
|
304 |
|
|
|
253 |
|
|
|
|
Inventories at FIFO Cost |
|
|
2,334 |
|
|
|
1,781 |
|
Excess of FIFO over LIFO Cost |
|
|
(128 |
) |
|
|
(62 |
) |
|
|
|
Total |
|
$ |
2,206 |
|
|
$ |
1,719 |
|
|
|
|
The increase in the excess of FIFO over LIFO cost is primarily the result of cost increases in
certain raw materials required for glyphosate and selective chemistry herbicide production.
NOTE 6. GOODWILL AND OTHER INTANGIBLE ASSETS
The fiscal year 2008 annual goodwill impairment test was performed as of March 1, 2008, and no
indications of goodwill impairment existed as of that date. Changes in the net carrying amount of
goodwill for the first nine months of fiscal year 2008, by segment, are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Seeds and |
|
|
Agricultural |
|
|
|
|
(Dollars in millions) |
|
Genomics |
|
|
Productivity |
|
|
Total |
|
|
Balance as of Aug. 31, 2007 |
|
$ |
2,559 |
|
|
$ |
66 |
|
|
$ |
2,625 |
|
Acquisition Activity (See Note 3) |
|
|
71 |
|
|
|
|
|
|
|
71 |
|
Effect of Foreign Currency Translation Adjustments |
|
|
73 |
|
|
|
|
|
|
|
73 |
|
|
Balance as of May 31, 2008 |
|
$ |
2,703 |
|
|
$ |
66 |
|
|
$ |
2,769 |
|
|
Information regarding the companys other intangible assets is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of May 31, 2008 |
|
|
As of Aug. 31, 2007 |
|
|
|
Carrying |
|
|
Accumulated |
|
|
|
|
|
|
Carrying |
|
|
Accumulated |
|
|
|
|
(Dollars in millions) |
|
Amount |
|
|
Amortization |
|
|
Net |
|
|
Amount |
|
|
Amortization |
|
|
Net |
|
|
|
|
Acquired Germplasm |
|
$ |
1,047 |
|
|
$ |
(578 |
) |
|
$ |
469 |
|
|
$ |
1,028 |
|
|
$ |
(547 |
) |
|
$ |
481 |
|
Acquired
Biotechnology
Intellectual Property |
|
|
929 |
|
|
|
(523 |
) |
|
|
406 |
|
|
|
900 |
|
|
|
(457 |
) |
|
|
443 |
|
Trademarks |
|
|
334 |
|
|
|
(72 |
) |
|
|
262 |
|
|
|
320 |
|
|
|
(60 |
) |
|
|
260 |
|
Customer Relationships |
|
|
273 |
|
|
|
(60 |
) |
|
|
213 |
|
|
|
250 |
|
|
|
(40 |
) |
|
|
210 |
|
Other |
|
|
52 |
|
|
|
(27 |
) |
|
|
25 |
|
|
|
39 |
|
|
|
(18 |
) |
|
|
21 |
|
|
|
|
Total |
|
$ |
2,635 |
|
|
$ |
(1,260 |
) |
|
$ |
1,375 |
|
|
$ |
2,537 |
|
|
$ |
(1,122 |
) |
|
$ |
1,415 |
|
|
|
|
The increases in other intangible assets during the first nine months of 2008 resulted primarily
from the acquisitions described in Note 3 Business Combinations.
11
|
|
|
MONSANTO COMPANY |
|
THIRD QUARTER 2008 FORM 10-Q |
|
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED (continued)
Total amortization expense of other intangible assets was $39 million in third quarter of fiscal
year 2008 and $36 million in third quarter of fiscal year 2007. Total amortization expense of other
intangible assets for the nine months ended May 31, 2008, and May 31, 2007, was $123 million and
$106 million, respectively. The estimated intangible asset amortization expense for fiscal year
2008 through fiscal year 2012 for owned assets at May 31, 2008, is as follows:
|
|
|
|
|
|
Year ending Aug. 31, |
|
|
|
(Dollars in millions) |
|
Amount |
|
|
2008 |
|
$ |
160 |
|
2009 |
|
|
145 |
|
2010 |
|
|
140 |
|
2011 |
|
|
135 |
|
2012 |
|
|
95 |
|
|
During second quarter 2008, Monsanto purchased a 19 percent interest in a seed supplier that
produces, conditions, and distributes corn and soybean seeds. Monsanto is accounting for this
investment as an equity method investment as Monsanto has the ability to exercise significant
influence over the seed supplier. As of May 31, 2008, the carrying value of this investment is
recorded in other assets in the Condensed Statements of Consolidated Financial Position at its
carrying value of $50 million. From the date of the investment through May 31, 2008, Monsanto
purchased $78 million of inventory from the seed supplier. As of May 31, 2008,
the amount payable to the seed supplier is less than $1 million and is recorded in accounts payable
in the Condensed Statements of Consolidated Financial Position.
During second quarter 2008, Monsanto received $38 million of Solutia common stock as part of the
settlement of its claims against Solutia. This investment is considered available-for-sale and is
recorded in other current assets in the Condensed Statements of Consolidated Financial Position as
of May 31, 2008, at its fair value of $32 million. See Note 16 Commitments and Contingencies
for further discussion of this Solutia-related gain.
During first quarter 2008, Monsanto invested in long-term equity securities, which are considered
available-for-sale. As of May 31, 2008, these long-term equity securities are recorded in other
assets in the Condensed Statements of Consolidated Financial Position at its fair value of $24
million. The sale of these long-term equity securities is restricted through Oct. 31, 2008. Net
unrealized losses of $1 million are included in accumulated other comprehensive income (loss) in
shareowners equity related to this investment as of May 31, 2008. As of Aug. 31, 2007, there were
no long-term equity securities classified as available-for-sale.
In first quarter 2008, Monsanto entered into an agreement on corn herbicide tolerance and insect
control trait technologies with Pioneer Hi-Bred International, Inc., a wholly-owned subsidiary of
E. I. du Pont de Nemours and Company. Among its provisions, the agreement modified certain existing
corn license agreements between the parties, included provisions under which the parties agreed not
to assert certain intellectual property rights against each other, and granted each party the right
to use certain regulatory data of the other in order to develop additional products. As a result of
the new agreement which requires fixed annual payments, the company recorded a receivable and
deferred revenue of $635 million in first quarter 2008. Cumulative cash receipts will be $725
million over an eight-year period. Revenue of $60 million related to this agreement was recorded in
the first nine months of 2008. As of May 31, 2008, the remaining receivable balance is $624
million. The majority of this balance is included in long-term receivables, and the current portion
is included in trade receivables. As of May 31, 2008, the remaining deferred revenue balance is
$575 million. The majority of this balance is included in long-term deferred revenue, and the
current portion is included in deferred revenues in the Condensed Statements of Consolidated
Financial Position. The interest portion of this receivable is reported in interest income and
totaled $16 million for the nine months ended May 31, 2008, in the Statements of Consolidated
Operations.
12
|
|
|
MONSANTO COMPANY |
|
THIRD QUARTER 2008 FORM 10-Q |
|
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED (continued)
In third quarter 2008, Monsanto and Syngenta entered into a Roundup Ready 2 Yield Soybean License
Agreement. The agreement grants Syngenta access to Monsantos RR2 Yield Soybean technology in
consideration of royalty payments from Syngenta, based on sales. Under this agreement Syngenta will
fulfill the contractual sales volumes over a nine year period. The minimum obligation from Syngenta over this period is $81 million. As a result of this
agreement, the company recorded a long term receivable and long term deferred revenue at the net
present value of $66 million in third quarter 2008.
In June 2006, the FASB issued FIN No. 48, Accounting for Uncertainty in Income Taxesan
interpretation of FASB Statement No. 109 (FIN 48). As required, the Company adopted the provisions
of FIN 48 as of Sept. 1, 2007. As a result of the implementation of FIN 48, Monsanto recorded a
charge to retained deficit of $25 million, primarily attributable to liabilities related to
interest and penalties on certain income tax matters. The total amount of unrecognized tax benefits
as of the date of adoption on Sept. 1, 2007, was $256 million, of which $139 million would favorably
impact the effective tax rate if recognized. It is expected that the amount of unrecognized tax
benefits will change in the next 12 months. However, management does not expect the change to have
a significant impact on Monsantos consolidated financial statements.
Monsanto recognizes accrued interest and penalties related to unrecognized tax benefits as a
component of income tax expense. This policy did not change with the adoption of FIN 48. Monsanto
had approximately $55 million accrued for interest and penalties as of Sept. 1, 2007.
Monsanto operates in various countries throughout the world and, as a result, files income tax
returns in numerous jurisdictions. These tax returns are subject to examination by various federal,
state and local tax authorities. For Monsantos major tax jurisdictions, the tax years that remain
subject to examination are shown below:
|
|
|
|
|
|
Jurisdiction |
|
Open Tax Years |
|
|
|
Argentina |
|
|
2000 - 2007 |
|
U.S. state and local income taxes |
|
|
2000 - 2007 |
|
Brazil |
|
|
2001 - 2007 |
|
Belgium |
|
|
2002 - 2007 |
|
U.S. federal income tax |
|
|
2005 - 2007 |
|
|
During the first nine months of 2008, total unrecognized tax benefits increased by $128 million, of
which $108 million would favorably impact the effective tax rate if recognized, primarily as a
result of the tax consequences of the settlement of Monsantos claims in the Solutia bankruptcy and
a transfer pricing item. See Note 16 Commitments and Contingencies for further discussion of
the Solutia bankruptcy.
Management regularly assesses the likelihood that deferred tax assets will be recovered from future
taxable income. To the extent management believes that it is more likely than not that a deferred
tax asset will not be realized, a valuation allowance is established. At the beginning of fiscal
2008, Argentina had a valuation allowance of $43 million for the deferred tax assets related to net
operating loss carryforwards. However, based on improvements in Monsanto Argentinas operations,
management now believes it is more likely than not that such deferred tax assets will be realized.
Accordingly, the previously recorded $43 million valuation allowance was reversed in third quarter
2008.
NOTE 10. DEBT AND OTHER CREDIT ARRANGEMENTS
In May 2005, Monsanto filed a new shelf registration with the SEC (2005 shelf registration) that
allowed the company to issue up to $2.0 billion of debt, equity and hybrid offerings (including
debt securities of $950 million remaining available under the May 2002 shelf registration
statement). In April 2008, Monsanto issued $300 million of 5.125% Senior Notes under the 2005 shelf
registration, which are due on April 15, 2018 (5.125% 2018 Senior Notes). The net proceeds from the
sale of the 5.125% 2018 Senior Notes will be used to finance the expansion of corn seed production
facilities. Also in April 2008, Monsanto issued $250 million of 5.875% Senior Notes under the 2005
shelf registration, which are due on April 15, 2038 (5.875% 2038 Senior Notes). The net proceeds
from the sale of the 5.875% 2038 Senior Notes were used to repay $238 million of 4% Senior Notes
that were due on May 15, 2008. As of May 31, 2008, $1 billion remained available under the 2005
shelf registration.
13
|
|
|
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED (continued)
In September 2007, the company entered into forward starting interest rate swaps with a total
notional amount of $500 million, which were accounted for as derivatives under SFAS 133, as
amended. The swaps were terminated in April 2008 at the time of issuance of the 5.125% 2018 Senior
Notes and the 5.875% 2038 Senior Notes. Realized losses net of tax of $29 million were recorded in
accumulated other comprehensive income (loss) to reflect the after-tax losses of the forward
starting interest rate swaps. The realized losses will be recorded in the Statement of Consolidated
Operations over the life of the debt instruments.
NOTE 11. POSTRETIREMENT BENEFITS PENSIONS, HEALTH CARE AND OTHER
The majority of Monsantos employees are covered by noncontributory pension plans sponsored by the
company. The company also provides certain postretirement health care and life insurance benefits
for retired employees through insurance contracts. The companys net periodic benefit cost for
pension benefits, and health care and other postretirement benefits include the following
components:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended May 31, 2008 |
|
|
Three Months Ended May 31, 2007 |
|
Pension Benefits |
|
|
|
|
|
Outside the |
|
|
|
|
|
|
|
|
|
|
Outside the |
|
|
|
|
(Dollars in millions) |
|
U.S. |
|
|
U.S. |
|
|
Total |
|
|
U.S. |
|
|
U.S. |
|
|
Total |
|
|
|
|
Service Cost for Benefits Earned During the Period |
|
$ |
9 |
|
|
$ |
1 |
|
|
$ |
10 |
|
|
$ |
7 |
|
|
$ |
2 |
|
|
$ |
9 |
|
Interest Cost on Benefit Obligation |
|
|
23 |
|
|
|
3 |
|
|
|
26 |
|
|
|
19 |
|
|
|
2 |
|
|
|
21 |
|
Assumed Return on Plan Assets |
|
|
(26 |
) |
|
|
(4 |
) |
|
|
(30 |
) |
|
|
(22 |
) |
|
|
(4 |
) |
|
|
(26 |
) |
Amortization of Unrecognized Net Loss |
|
|
9 |
|
|
|
1 |
|
|
|
10 |
|
|
|
8 |
|
|
|
1 |
|
|
|
9 |
|
|
|
|
Total Net Periodic Benefit Cost |
|
$ |
15 |
|
|
$ |
1 |
|
|
$ |
16 |
|
|
$ |
12 |
|
|
$ |
1 |
|
|
$ |
13 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended May 31, 2008 |
|
|
Nine Months Ended May 31, 2007 |
|
Pension Benefits |
|
|
|
|
|
Outside the |
|
|
|
|
|
|
|
|
|
|
Outside the |
|
|
|
|
(Dollars in millions) |
|
U.S. |
|
|
U.S. |
|
|
Total |
|
|
U.S. |
|
|
U.S. |
|
|
Total |
|
|
|
|
Service Cost for Benefits Earned During the Period |
|
$ |
29 |
|
|
$ |
4 |
|
|
$ |
33 |
|
|
$ |
27 |
|
|
$ |
4 |
|
|
$ |
31 |
|
Interest Cost on Benefit Obligation |
|
|
71 |
|
|
|
9 |
|
|
|
80 |
|
|
|
72 |
|
|
|
8 |
|
|
|
80 |
|
Assumed Return on Plan Assets |
|
|
(81 |
) |
|
|
(12 |
) |
|
|
(93 |
) |
|
|
(84 |
) |
|
|
(11 |
) |
|
|
(95 |
) |
Amortization of Unrecognized Net Loss |
|
|
28 |
|
|
|
2 |
|
|
|
30 |
|
|
|
31 |
|
|
|
2 |
|
|
|
33 |
|
|
|
|
Total Net Periodic Benefit Cost |
|
$ |
47 |
|
|
$ |
3 |
|
|
$ |
50 |
|
|
$ |
46 |
|
|
$ |
3 |
|
|
$ |
49 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Health Care and Other Postretirement Benefits |
|
Three
Months Ended May 31, |
|
|
Nine
Months Ended May 31, |
|
(Dollars in millions) |
|
2008 |
|
|
2007 |
|
|
2008 |
|
|
2007 |
|
|
|
|
Service Cost for Benefits Earned During the Period |
|
$ |
3 |
|
|
$ |
3 |
|
|
$ |
9 |
|
|
$ |
9 |
|
Interest Cost on Benefit Obligation |
|
|
4 |
|
|
|
4 |
|
|
|
12 |
|
|
|
14 |
|
Amortization of Unrecognized Net Gain |
|
|
|
|
|
|
(2 |
) |
|
|
(1 |
) |
|
|
(8 |
) |
|
|
|
Total Net Periodic Benefit Cost |
|
$ |
7 |
|
|
$ |
5 |
|
|
$ |
20 |
|
|
$ |
15 |
|
|
|
|
Monsanto
contributed $60 million to its U.S. qualified plan in each of
the nine month periods ended May 31, 2008, and May 31, 2007, and $4 million and $3 million to plans outside the United States in the first nine months of
2008 and 2007, respectively. As of May 31, 2008, management expects to make additional
contributions of approximately $9 million to the companys pension plans outside the United States
in fiscal year 2008.
14
|
|
|
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED (continued)
NOTE 12. STOCK-BASED COMPENSATION PLANS
The following table shows total stock-based compensation expense included in the Statements of
Consolidated Operations for the three months and nine months ended May 31, 2008, and May 31, 2007.
Stock-based compensation cost capitalized in inventories was $3 million as of May 31, 2008.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three
Months Ended May 31, |
|
|
Nine
Months Ended May 31, |
|
(Dollars in millions) |
|
2008 |
|
|
2007 |
|
|
2008 |
|
|
2007 |
|
|
|
|
Cost of Goods Sold |
|
$ |
2 |
|
|
$ |
2 |
|
|
$ |
6 |
|
|
$ |
6 |
|
Selling, General and Administrative Expenses |
|
|
16 |
|
|
|
13 |
|
|
|
46 |
|
|
|
38 |
|
Research and Development Expenses |
|
|
5 |
|
|
|
4 |
|
|
|
12 |
|
|
|
10 |
|
|
|
|
Pre-Tax Stock-Based Compensation Expense |
|
|
23 |
|
|
|
19 |
|
|
|
64 |
|
|
|
54 |
|
Income Tax Benefit |
|
|
(8 |
) |
|
|
(7 |
) |
|
|
(23 |
) |
|
|
(19 |
) |
|
|
|
Net Stock-Based Compensation Expense |
|
$ |
15 |
|
|
$ |
12 |
|
|
$ |
41 |
|
|
$ |
35 |
|
|
|
|
During the nine months ended May 31, 2008, Monsanto granted 2,487,310 stock options, 1,254 shares
of restricted stock and 200,995 restricted stock units to employees under the Monsanto Company
Long-Term Incentive Plan (LTIP), as amended, and the Monsanto Company 2005 Long-Term Incentive Plan
(2005 LTIP). In addition, 15,042 shares of deferred stock and 1,183 shares of restricted stock were
granted to directors under the Monsanto Non-Employee Director Equity Incentive Compensation Plan
(Director Plan).
The weighted-average grant-date fair value of non-qualified stock options granted during the nine
months ended May 31, 2008, was $29.92 per share. Pre-tax unrecognized compensation expense for
stock options, net of estimated forfeitures, was $60 million as of May 31, 2008, and will be
recognized as expense over a weighted-average period of 2.1 years.
The weighted-average grant-date fair value of restricted stock and restricted stock units granted
during the nine months ended May 31, 2008, was $131.54 and $91.76, respectively, per share. Pre-tax
unrecognized compensation expense, net of estimated forfeitures, for nonvested restricted stock and
restricted stock units was $2 million and $24 million, respectively, as of May 31, 2008, which will
be recognized as expense over the weighted-average remaining requisite service periods. The
weighted-average remaining requisite service periods for nonvested restricted stock and restricted
stock units was 2.1 years as of May 31, 2008. The weighted-average grant-date fair value of
directors deferred stock and directors restricted stock granted during the nine months ended May
31, 2008, was $71.64 and $69.74, respectively, per share. Pre-tax unrecognized compensation expense
for awards granted under the Director Plan was less than $1 million as of May 31, 2008, and will be
recognized as expense over a weighted-average period of 3 months.
NOTE 13. COMPREHENSIVE INCOME
Comprehensive income includes all nonshareowner changes in equity and consists of net income,
foreign currency translation adjustments, gains and losses on the foreign currency hedge of the
companys net investment in a foreign subsidiary, net unrealized gains and losses on
available-for-sale securities, and net derivative gains or losses on cash flow hedges not yet
realized. Information regarding comprehensive income is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three
Months Ended May 31, |
|
|
Nine
Months Ended May 31, |
|
(Dollars in millions) |
|
2008 |
|
|
2007 |
|
|
2008 |
|
|
2007 |
|
|
|
|
Comprehensive Income |
|
$ |
854 |
|
|
$ |
745 |
|
|
$ |
2,747 |
|
|
$ |
1,478 |
|
|
|
|
15
|
|
|
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED (continued)
The components of accumulated other comprehensive income (loss) are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
As
of May 31, |
|
|
As of Aug. 31, |
|
(Dollars in millions) |
|
2008 |
|
|
2007 |
|
|
|
|
Accumulated Foreign Currency Translation Adjustments |
|
$ |
346 |
|
|
$ |
(154 |
) |
Net Unrealized Loss on Investments, Net of Tax |
|
|
(3 |
) |
|
|
|
|
Net Accumulated Derivative Gain (Loss), Net of Tax |
|
|
25 |
|
|
|
(14 |
) |
Funded Status of Pension and Other Post Retirement Benefit Liabilities, Net of Tax |
|
|
(194 |
) |
|
|
(209 |
) |
|
|
|
Accumulated Other Comprehensive Income (Loss) |
|
$ |
174 |
|
|
$ |
(377 |
) |
|
|
|
NOTE 14. EARNINGS PER SHARE
Basic earnings per share (EPS) was computed using the weighted-average number of common shares
outstanding during the period shown in the table below. For the three months and nine months ended
May 31, 2008, and May 31, 2007, diluted EPS was computed taking into account the effect of dilutive
potential common shares, as shown in the table below. Potential common shares consist primarily of
stock options using the treasury stock method and are excluded if their effect is antidilutive.
Less than 0.1 million and approximately 0.1 million stock options were excluded from the
computations of dilutive potential common shares as they were antidilutive for the three months and
nine months ended May 31, 2008, respectively. Approximately 0.2 million and 4.2 million stock
options were excluded from the computations of dilutive potential common shares as they were
antidilutive for the three months and nine months ended May 31, 2007, respectively. Of those
antidilutive options, less than 0.1 million stock options were excluded from the computations of
dilutive potential common shares for the three months and nine months ended May 31, 2008, and May
31, 2007, as their exercise prices were greater than the average market price of common shares for
the period.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three
Months Ended May 31, |
|
|
Nine
Months Ended May 31, |
|
|
|
2008 |
|
|
2007 |
|
|
2008 |
|
|
2007 |
|
|
|
|
Weighted-Average Number of Common Shares |
|
|
549.0 |
|
|
|
544.4 |
|
|
|
547.6 |
|
|
|
543.7 |
|
Dilutive Potential Common Shares |
|
|
11.0 |
|
|
|
10.8 |
|
|
|
11.3 |
|
|
|
10.7 |
|
|
|
|
NOTE 15. SUPPLEMENTAL CASH FLOW INFORMATION
Cash payments for interest and taxes were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended May 31, |
|
(Dollars in millions) |
|
2008 |
|
|
2007 |
|
|
Interest |
|
$ |
65 |
|
|
$ |
64 |
|
Taxes |
|
|
522 |
|
|
|
335 |
|
|
In second
quarter 2007, intangible assets and a liability in the amount of
$15 million were recorded
as a result of minimum payment provisions under a license agreement.
16
|
|
|
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED (continued)
NOTE 16. COMMITMENTS AND CONTINGENCIES
Litigation and Indemnification: Monsanto is involved in various legal proceedings that arise in the
ordinary course of its business, as well as proceedings that management has considered to be
material under SEC regulations. These proceedings include proceedings to which Monsanto is a party
in its own name as well as proceedings to which Pharmacia or Solutia is a party but that Monsanto
manages and for which Monsanto is responsible. Some of the lawsuits seek damages in very large
amounts, or seek to restrict the companys business activities. Although the ultimate liabilities
resulting from such proceedings may be significant to profitability in the period recognized,
management does not anticipate they will have a material adverse effect on Monsantos consolidated
financial position or liquidity. Specific information with respect to these proceedings appears
below and in Part II Item 1 Legal Proceedings of this report.
As described in Monsantos Report on Form 10-K for the fiscal year ended Aug. 31, 2007, and
Monsantos Reports on Form 10-Q for the quarterly periods ended Nov. 30, 2007, and Feb. 29, 2008,
certain Korean veterans of the Vietnam War have filed suit in Seoul, South Korea, against The Dow
Chemical Company and the former Monsanto Company. Three complaints filed in October 1999 are being
handled collectively and involve approximately 16,800 plaintiffs. The plaintiffs allege that they
were exposed to Agent Orange and that as a result they suffered injuries or their children suffered
birth defects. In 2002, the Seoul District Court ruled in favor of the defendants and dismissed all
claims on the basis of lack of causation and statutes of limitations. On Jan. 26, 2006, the Seoul
High Court affirmed the denial of any recovery for approximately 10,000 plaintiffs, stating they
had failed to show that any injuries they claimed were caused by exposure to the Agent Orange. In
addition, for approximately 6,800 plaintiffs, the Seoul High Court reversed the decision of the
Seoul District Court and awarded damages jointly against Dow Chemical and the former Monsanto
Company in the amount of $58 million (subject to currency exchange rates), plus prejudgment
interest in the amount of approximately $28 million (subject to currency exchange rates) and post
judgment interest at the rate of 20 percent per annum. On Feb. 17, 2006, Dow Chemical and the
former Monsanto Company filed a notice of appeal with the Korean Supreme Court, as did the
plaintiffs. Management does not believe it is probable that Monsanto will incur this liability, and
accordingly, has not recorded a charge for the judgment. As noted, certain dollar amounts have been
calculated based on an exchange rate of 1,041.67 South Korean won per dollar and will fluctuate with
exchange rates in the future.
As described in Monsantos Report on Form 10-K for the fiscal year ended Aug. 31, 2007, and
Monsantos Reports on Form 10-Q for the quarterly periods ended Nov. 30, 2007, and Feb. 29, 2008,
on June 23, 2004, two former employees of Monsanto and Pharmacia filed a purported class action
lawsuit in the U.S. District Court for the Southern District of Illinois against Monsanto and the
Monsanto Company Pension Plan, which is referred to as the Pension Plan. The suit claims that the
Pension Plan has violated the age discrimination and other rules under the Employee Retirement
Income Security Act of 1974 from Jan. 1, 1997 (when the Pension Plan was sponsored by Pharmacia,
then known as Monsanto Company) and continuing to the present. In January 2006, a separate group of
former employees of Pharmacia filed a similar purported class action lawsuit in the U.S. District
Court for the Southern District of Illinois against Pharmacia, the Pharmacia Cash Balance Plan, and
other defendants. On July 7, 2006, the plaintiffs amended their lawsuit to add Monsanto and the
Pension Plan as additional defendants. On Sept. 1, 2006, the Court consolidated these lawsuits with
two purported class action lawsuits also pending in the same Court against the Solutia Company
Pension Plan, under Walker v. Monsanto, the first filed case. The court conducted a class
certification hearing on Sept. 12, 2007. Prior to the hearing, all parties agreed the case should
proceed as a class action and also agreed on a definition of the respective classes. The court
originally issued a scheduling order that set a deadline of June 2008 for parties to file
dispositive motions. Trial is scheduled to begin Oct. 27, 2008. The trial judge modified the
scheduling order and dispositive motions are now due in August 2008. The trial date is unchanged.
Matters related to Solutia Inc.: Pursuant to the Sept. 1, 2000, Separation Agreement between
Monsanto and Pharmacia, as amended (Separation Agreement), Monsanto was required to indemnify
Pharmacia for liabilities that Solutia assumed from Pharmacia under a Distribution Agreement
entered into between those companies in connection with the spinoff of Solutia on Sept. 1, 1997, as
amended (Distribution Agreement), to the extent that Solutia fails to pay, perform or discharge
those liabilities. Those liabilities are referred to as Solutias Assumed Liabilities. Solutias
Assumed Liabilities may include, among others, litigation, environmental remediation, and certain
retiree liabilities relating to individuals who were employed by Pharmacia prior to the Solutia
spinoff.
17
|
|
|
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED (continued)
On Dec. 17, 2003, Solutia and 14 of its U.S. subsidiaries filed voluntary petitions for
reorganization under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the
Southern District of New York. In the Chapter 11 proceeding,
Solutia sought relief from paying certain liabilities, including some of Solutias Assumed
Liabilities. In accordance with a plan of reorganization (Plan) approved by the Bankruptcy Court on
Nov. 29, 2007, Solutia emerged from bankruptcy protection on Feb. 28, 2008.
Under the Plan, and with regard to Solutias Assumed Liabilities, Monsanto has (i) accepted
financial responsibility for toxic tort litigation relating to Pharmacias chemical business that
occurred prior to Sept. 1, 1997; (ii) accepted financial responsibility for environmental
remediation obligations at sites relating to Pharmacias chemical business which Solutia never
owned or operated; and (iii) agreed to share financial responsibility for off-site environmental
remediation costs in Anniston, Alabama, and Sauget, Illinois. The agreement to share financial
responsibility for the Anniston and Sauget sites provides that Solutia would pay the first $50
million, Monsanto would pay the next $50 million minus amounts Monsanto paid toward these sites
during Solutias Chapter 11 case, and Solutia would pay the next $325 million, if needed, after
which Monsanto and Solutia would share responsibility for costs equally. Monsanto had already
incurred in excess of $50 million for offsite environmental remediation and related legal costs in
Anniston and Sauget when Solutia emerged from bankruptcy.
Under the Plan, upon Solutias emergence from bankruptcy, in satisfaction of Monsantos claims
against Solutia, Monsanto received from Solutia: (i) approximately $163 million in cash (which
represents proceeds from a rights offering from Solutias equity holders, third-party
reimbursements and Monsantos administrative claim for environmental remediation payments it made
in Anniston and Sauget during Solutias Chapter 11 proceeding in excess of $50 million); (ii)
approximately 2.5 million shares of common stock of Solutia, representing that portion of the
equity of reorganized Solutia allocated to Monsanto under the Plan which was not purchased by
Solutias equity holders; (iii) a credit in an amount in excess of $30 million against certain
future payments by Monsanto to Solutia under supply contracts used in the production of an
intermediate for glyphosate at Monsantos facility at Chocolate Bayou, Texas (described further
below under Other Solutia-Related Matters); (iv) a release for Monsanto and Pharmacia from certain
legacy liabilities associated with Pharmacias chemical business that arose prior to Sept. 1, 1997,
including liabilities related to retiree medical, retiree life insurance, and disability benefits
for individuals who retired or became disabled prior to Sept. 1, 1997; and (v) a release for
Monsanto and Pharmacia for the litigation filed by Solutia, the Official Committee of Retirees, and
the Official Committee of Equity Holders of Solutia against Monsanto and Pharmacia. Since Monsanto
had previously recognized the expenses for which it received reimbursement, the reimbursed amounts
resulted in an after-tax gain of approximately $130 million ($210 million pretax) or $0.23 per
share.
In September 2003, in connection with a global settlement of certain PCB litigation: Sabrina
Abernathy et al. v. Monsanto Company et al. (a group of consolidated cases in the Circuit Court of
Etowah County, Alabama); and Antonia Tolbert et al. v. Monsanto Company et al. (in the U.S.
District Court for the Northern District of Alabama), Solutia agreed to pay $50 million of the
settlement amount over the next 11 years or more and to issue warrants to Monsanto for the purchase
of up to 10 million shares of Solutia common stock, at an exercise price of $1.104 per share, which
it did not issue. Under the Plan, Solutia is obligated to continue making its settlement payments
under the terms of the Plan but is no longer required to issue the warrants to Monsanto.
18
|
|
|
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED (continued)
Prior to Solutias emergence from bankruptcy, Monsanto assumed the management and defense of
certain third-party tort litigation and funded some of Solutias environmental obligations. In
December 2004, Monsanto determined that it was appropriate to establish a reserve for expenses
related to third-party tort litigation and environmental liabilities based on the best estimates by
Monsantos management with input from its legal and other outside advisors. Accordingly, a charge
in the amount of $284 million was recorded in Monsantos first quarter fiscal 2005 results. As of
May 31, 2008, $199 million was recorded in the Condensed Statements of Consolidated Financial
Position for the remaining Solutia-related reserve and other
non-Solutia environmental reserves ($49 million in miscellaneous short-term accruals and $150 million in the long-term
portion of environmental and related litigation reserve). The amount reported in the long-term
portion of environmental and related litigation reserve as of Aug. 31, 2007, includes $16 million
of non-Solutia related environmental reserves that were previously classified as other liabilities.
A portion of the charge was discounted, using a risk-free discount rate of 3.5 percent. The
remaining portion of the charge was not subject to discounting because of uncertainties in the
timing of cash outlay or was paid during first quarter of fiscal year 2005. In third quarter 2008,
interest expense of $2 million was recognized for the accretion of the discounted amount. The
following table provides a rollforward of the environmental liability since the initial charge
recorded in fiscal 2005:
Rollforward of Liability:
|
|
|
|
|
|
(Dollars in millions) |
|
|
|
|
|
Total Charge Recognized in First Quarter Fiscal Year 2005 |
|
$ |
284 |
|
|
Payments |
|
|
(49 |
) |
Accretion |
|
|
4 |
|
|
Balance Aug. 31, 2005 |
|
$ |
239 |
|
Payments |
|
|
(34 |
) |
Accretion |
|
|
5 |
|
|
Balance Aug. 31, 2006 |
|
$ |
210 |
|
Payments |
|
|
(33 |
) |
Accretion |
|
|
3 |
|
Additional charge recognized in fiscal year 2007 |
|
|
2 |
|
|
Balance Aug. 31, 2007 |
|
$ |
182 |
|
Payments |
|
|
(19 |
) |
Accretion |
|
|
2 |
|
Additional charge recognized in fiscal year 2008 |
|
|
5 |
|
|
Remaining
Solutia-Related Reserve as of May 31, 2008 |
|
$ |
170 |
|
|
Non-Solutia
Environmental Reserve |
|
$ |
29 |
|
|
Total
Environmental and Related Litigation Reserve as of May 31, 2008 |
|
$ |
199 |
|
|
In addition to the liability, Monsanto incurred legal and other costs related to the Chapter 11
proceeding and its Solutia-related indemnification obligations to Pharmacia. These costs, along
with excess amounts for the Sauget and Anniston remediation described above, were expensed as
incurred because the potential future costs to Monsanto to protect its interests could not be
reasonably estimated. These legal and other costs, together with the recorded liability, have been
reflected in the Statements of Consolidated Operations as Solutia-related expenses.
Monsanto believes that the recorded liability represents the discounted cost that Monsanto would
expect to incur in connection with these litigation and environmental matters. Monsanto expects to
pay for these potential liabilities over time as the various legal proceedings are resolved and
remediation is performed at the various environmental sites. Actual costs to Monsanto may differ
materially from this estimate. Further, additional litigation or environmental matters that are not
reflected in the liability may arise in the future, and Monsanto may also manage, settle, or pay
judgments or damages with respect to litigation or environmental matters in order to mitigate
contingent potential liability and protect Pharmacia and Monsanto.
The liability as of Feb. 29, 2008, does not reflect any insurance reimbursements or any recoveries
Monsanto might receive through actions that it is pursuing on Pharmacias behalf with regard to the
Anniston, Alabama, Sauget, Illinois, and Lower Passaic River, New Jersey, sites. Receivables of $3
million were recorded as of May 31, 2008, in other assets, for the anticipated insurance
reimbursement of a portion of Monsantos settlement payments for certain litigation related to
Anniston, Alabama. Monsanto expects these receivables to be paid over three years, in quarterly
installments, which began in March 2005. Monsanto has received net insurance proceeds of $156
million.
19
|
|
|
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED (continued)
Solutia-related Litigation Obligations: Included in the liability are amounts related to certain
third-party tort litigation, including lawsuits involving polychlorinated biphenyls (PCBs),
dioxins, and other chemical and premises liability litigation. The following describes the
significant litigation matters reflected in the liability.
As described in Monsantos Report on Form 10-K for the fiscal year ended Aug. 31, 2007, and
Monsantos Reports on Form 10-Q for the quarterly periods ended Nov. 30, 2007, and Feb. 29, 2008,
on Dec. 17, 2004, 15 plaintiffs filed a purported class action lawsuit, styled Virdie Allen, et al.
v. Monsanto, et al., in the Putnam County, West Virginia, state court against Monsanto, Pharmacia
and seven other defendants. Monsanto is named as the successor in interest to the liabilities of
Pharmacia. The alleged class consists of all current and former residents, workers, and students
who, between 1949 and the present, were allegedly exposed to dioxins/furans contamination in
counties surrounding Nitro, West Virginia. The complaint alleges that the source of the
contamination is a chemical plant in Nitro, formerly owned and operated by Pharmacia and later by
Flexsys, a joint venture between Solutia and Akzo Nobel Chemicals, Inc. (Akzo Nobel). Akzo Nobel
and Flexsys were named defendants in the case but Solutia was not, due to its then pending
bankruptcy proceeding. The suit seeks damages for property cleanup costs, loss of real estate
value, funds to test property for contamination levels, funds to test for human contamination, and
future medical monitoring costs. The complaint also seeks an injunction against further
contamination and punitive damages. Akzo Nobel and the Flexsys group of defendants tendered their
cases to Monsanto for indemnification and defense. Monsanto agreed to indemnify and defend Akzo
Nobel and the Flexsys defendant group. The class action certification hearing was held on Oct. 29,
2007. On Oct. 1, 2007, 78 separate, single plaintiff civil actions were filed in Putnam County,
West Virginia, against Monsanto, Pharmacia, Akzo Nobel (and several of its affiliates), Flexsys
America Co. (and several of its affiliates), Solutia, and Apogee Coal Company, LLC. Except for the
name of the plaintiff, each complaint is identical and each alleges personal injury occasioned by
exposure to dioxin generated by the Nitro Plant during production of 2,4,5 T (1949-1969) and
thereafter. These cases are related to, and were filed in the same court as, the Allen action
described above. Akzo Nobel and Flexsys America have tendered their defense of the case to
Monsanto. Pursuant to preexisting agreements between the companies, Monsanto agreed to accept the
tenders of defense in the matters.
Solutia-related Environmental Obligations: Included in the liability are amounts related to certain
environmental liabilities, particularly expenses for environmental remediation of sites Solutia
never owned or operated and sites beyond the property lines of Solutias current or former
operations. The following describes the significant environmental matters reflected in the
liability.
As described in Monsantos Report on Form 10-K for the fiscal year ended Aug. 31, 2007, and
Monsantos Reports on Form 10-Q for the quarterly periods ended Nov. 30, 2007, and Feb. 29, 2008,
on Aug. 4, 2003, the U.S. District Court for the Northern District of Alabama approved a Revised
Partial Consent Decree (RPCD), pursuant to which Pharmacia and Solutia are obligated to perform PCB
residential cleanup work and a remedial investigation/feasibility study of PCB contamination in
Anniston, among other things. On March 25, 2004, Monsanto, acting on behalf of Pharmacia, entered
into an arrangement with the EPA and Solutia to perform certain environmental obligations at the
Anniston, Alabama, and Sauget, Illinois, sites under the RPCD and other orders where both Solutia
and Pharmacia are named parties. Under the Plan, Solutia is now managing these matters. Monsanto,
Solutia and the U.S. have agreed that the arrangement with EPA is moot and has been superseded by
the Plan.
As described in Monsantos Report on Form 10-K for the fiscal year ended Aug. 31, 2007, and
Monsantos Reports on Form 10-Q for the quarterly periods ended Nov. 30, 2007, and Feb. 29, 2008,
in May 2002, the EPA sent Monsanto and Solutia a notice of potential liability and offer to
negotiate for removal action regarding dioxin in the Kanawha River in Putnam and Kanawha counties,
West Virginia, which was premised on Pharmacias former operations at its Nitro, West Virginia,
manufacturing facility. The EPA, Monsanto and Pharmacia have negotiated a consent order under which
Monsanto is preparing an Engineering Evaluation/Cost Analysis Report, which will contain the
results of Monsantos investigation of dioxin contamination in the Kanawha River, the sources of
such contamination, an evaluation of removal options, and a recommended approach to removing or
otherwise addressing the contaminated sediments.
As described in Monsantos Report on Form 10-K for the fiscal year ended Aug. 31, 2007, and
Monsantos Reports on Form 10-Q for the quarterly periods ended Nov. 30, 2007, and Feb. 29, 2008,
Monsanto is performing various remedial activities at the IndustriPlex site in Woburn,
Massachusetts. In January 2006, the EPA published a Record of Decision identifying additional
remedial work it anticipates for the Aberjona River, which is downstream of the IndustriPlex site.
On
20
|
|
|
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED (continued)
behalf of Pharmacia, Monsanto entered into an agreement with the EPA, subject to court approval,
under which Monsanto and another party will perform this work.
Other Solutia-related Matters: Monsanto is a party to several agreements with Solutia for the
supply of raw materials and services used in the production of an intermediate for glyphosate at
Monsantos facility at Chocolate Bayou, Texas. In November 2007 and February 2008, Monsanto and
Solutia amended these agreements to provide that, subject to Solutias emergence from bankruptcy
under the Plan, the supply arrangements will terminate on Dec. 31, 2012, upon which time
Monsanto will be obligated to pay Solutia a $30 million termination fee, the net present value of
which is $26 million. Under Solutias Plan and with regard to the Solutia Assumed Liabilities,
Monsanto received a credit which offsets this termination fee as described above. The amendments to
the supply agreements also provide that Monsanto will purchase certain minimum volumes of raw
materials to produce disodium iminodiacetic acid, a key ingredient in the production of glyphosate.
These amendments became effective when Solutia emerged from bankruptcy protection.
Guarantees: Disclosure regarding the guarantees Monsanto provides for certain customer loans in the
United States, Brazil, Europe and Argentina can be found in Note 4 Customer Financing Programs
of this Form 10-Q. Except as described in that note, there have been no significant changes to
guarantees made by Monsanto since Aug. 31, 2007. Disclosures regarding these guarantees made by
Monsanto can be found in Note 21 Commitments and Contingencies of the notes to the
consolidated financial statements contained in Monsantos Report on Form 10-K for the fiscal year
ended Aug. 31, 2007. Information regarding Monsantos indemnification obligations to Pharmacia
under the Separation Agreement relating to Solutias Assumed Liabilities can be found above.
NOTE 17. SEGMENT INFORMATION
Monsanto conducts its worldwide operations through global businesses, which are aggregated into
reportable segments based on similarity of products, production processes, customers, distribution
methods and economic characteristics. The operating segments are aggregated into two reportable
segments: Seeds and Genomics, and Agricultural Productivity. The Seeds and Genomics segment
consists of the global seeds and related traits businesses and biotechnology platforms. Within the
Seeds and Genomics segment, Monsantos significant operating segments are corn seed and traits,
soybean seed and traits, vegetable and fruit seeds and all other crops seeds and traits. After the
acquisition of DPL in 2007, Monsanto identified cotton seed and traits as an additional significant
operating segment within the Seeds and Genomics segment. The Agricultural Productivity segment
consists of the crop protection products, the animal agriculture business and lawn-and-garden
herbicide products. Within the Agricultural Productivity segment, the significant operating
segments are Roundup and other glyphosate-based products and all other agricultural products. EBIT
is defined as earnings (loss) before interest and taxes and is the primary operating performance
measure for the two business segments. EBIT is useful to management in demonstrating the
operational profitability of the segments by excluding interest and taxes, which are generally
accounted for across the entire company on a consolidated basis. Sales between segments were not
significant. Certain selling, general and administrative expenses are allocated between segments
primarily by the ratio of segment sales to total Monsanto sales, consistent with the companys
historical practice. Based on the Seeds and Genomics segments increasing contribution to total
Monsanto operations, the allocation percentages were changed at the beginning of fiscal year 2008.
Data for the Seeds and Genomics and Agricultural Productivity reportable segments, as well as for
Monsantos significant operating segments, is presented in the table that follows.
21
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED (continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
(Dollars in millions) |
|
May 31, 2008 |
|
|
May 31, 2007 |
|
|
May 31, 2008 |
|
|
May 31, 2007 |
|
|
|
|
Net Sales(1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Corn seed and traits |
|
$ |
975 |
|
|
$ |
891 |
|
|
$ |
3,189 |
|
|
$ |
2,443 |
|
Soybean seed and traits |
|
|
447 |
|
|
|
325 |
|
|
|
1,064 |
|
|
|
868 |
|
Cotton seed and traits |
|
|
279 |
|
|
|
212 |
|
|
|
361 |
|
|
|
260 |
|
Vegetable and fruit seed |
|
|
185 |
|
|
|
170 |
|
|
|
521 |
|
|
|
444 |
|
All other crops seeds and traits |
|
|
161 |
|
|
|
114 |
|
|
|
293 |
|
|
|
207 |
|
|
|
|
Total Seeds and Genomics |
|
$ |
2,047 |
|
|
$ |
1,712 |
|
|
$ |
5,428 |
|
|
$ |
4,222 |
|
|
|
|
ROUNDUP and other glyphosate-based herbicides |
|
$ |
1,168 |
|
|
$ |
757 |
|
|
$ |
3,158 |
|
|
$ |
1,936 |
|
All other agricultural productivity products |
|
|
373 |
|
|
|
373 |
|
|
|
880 |
|
|
|
832 |
|
|
|
|
Total Agricultural Productivity |
|
$ |
1,541 |
|
|
$ |
1,130 |
|
|
$ |
4,038 |
|
|
$ |
2,768 |
|
|
|
|
Total |
|
$ |
3,588 |
|
|
$ |
2,842 |
|
|
$ |
9,466 |
|
|
$ |
6,990 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EBIT(2) (3) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Seeds and Genomics |
|
$ |
586 |
|
|
$ |
557 |
|
|
$ |
1,643 |
|
|
$ |
1,302 |
|
Agricultural Productivity |
|
|
502 |
|
|
|
242 |
|
|
|
1,488 |
|
|
|
423 |
|
|
|
|
Total |
|
$ |
1,088 |
|
|
$ |
799 |
|
|
$ |
3,131 |
|
|
$ |
1,725 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and Amortization Expense (4) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Seeds and Genomics |
|
$ |
99 |
|
|
$ |
74 |
|
|
$ |
292 |
|
|
$ |
250 |
|
Agricultural Productivity |
|
|
43 |
|
|
|
55 |
|
|
|
131 |
|
|
|
136 |
|
|
|
|
Total |
|
$ |
142 |
|
|
$ |
129 |
|
|
$ |
423 |
|
|
$ |
386 |
|
|
|
|
|
|
|
(1) |
|
Represents net sales from continuing operations. |
|
(2) |
|
EBIT is defined as earnings (loss) before interest and taxes; see the following
table for reconciliation. Earnings (loss) is intended to mean net income (loss) as presented
in the Statements of Consolidated Operations under generally accepted accounting principles.
EBIT is the primary operating performance measure for the two business segments. |
|
(3) |
|
Seeds and genomics EBIT includes income of $8 million and a loss of $5 million from
discontinued operations for the three months and nine months ended May 31, 2007, respectively. |
|
(4) |
|
Seeds and Genomics depreciation and amortization expense includes $3 million and $8
million from discontinued operations for the three months and nine months ended May 31, 2007,
respectively. |
A reconciliation of EBIT to net income for each period follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
(Dollars in millions) |
|
May 31, 2008 |
|
|
May 31, 2007 |
|
|
May 31, 2008 |
|
|
May 31, 2007 |
|
|
|
|
EBIT(1) |
|
$ |
1,088 |
|
|
$ |
799 |
|
|
$ |
3,131 |
|
|
$ |
1,725 |
|
Interest (Income) Expense Net |
|
|
(3 |
) |
|
|
1 |
|
|
|
(6 |
) |
|
|
7 |
|
Income Tax Provision(2) |
|
|
280 |
|
|
|
228 |
|
|
|
941 |
|
|
|
515 |
|
|
|
|
Net Income |
|
$ |
811 |
|
|
$ |
570 |
|
|
$ |
2,196 |
|
|
$ |
1,203 |
|
|
|
|
|
|
|
(1) |
|
Includes the loss from operations of discontinued businesses and pre-tax minority interest. |
|
(2) |
|
Includes the income tax provision from continuing operations, the income tax benefit on
minority interest and the income tax provision (benefit) from discontinued operations. |
NOTE 18. DISCONTINUED OPERATIONS
Divested Cotton Businesses: In conjunction with the DOJ consent decree received on May 31, 2007,
Monsanto agreed to divest its U.S. Stoneville and NexGen Branded Cotton Seed businesses. Monsanto
completed its acquisition of DPL as of June 1, 2007. The U.S. Stoneville and NexGen businesses were
part of the Seeds and Genomics segment. Monsanto sold its Stoneville and NexGen cotton seed brands
and related business assets on June 19, 2007, for $310 million and $7 million, respectively.
Monsanto also divested certain cotton germplasm that was acquired from DPLs cotton breeding
program, as required by the consent decree. Monsanto has retained certain rights to this germplasm.
The buyers of these assets are licensed to use our traits in their brands prospectively under a
royalty bearing agreement. During the nine months ended May 31, 2007, Monsanto included a loss of
$3 million net of taxes related to these businesses in discontinued operations.
22
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS UNAUDITED (continued)
NOTE 19. SUBSEQUENT EVENTS
In March 2008, Monsanto entered into a definitive agreement to acquire 100 percent of the
outstanding stock of De Ruiter Seeds Group, B.V. and a related company (De Ruiter). De Ruiter is a
leading protected-culture vegetable seeds company based in the Netherlands with operations
worldwide. The purchase price per the agreement is 546 million, which was reduced by net debt of
approximately 53 million or $82 million, resulting in a cash purchase price to be paid at closing
of 493 million or $769 million. Monsanto consummated the transaction with existing cash on June
13, 2008 after receiving approvals from the appropriate regulatory authorities.
In June 2008, Monsanto agreed to acquire Marmot, S.A., which operates Semillas Cristiani Burkard, a
privately-held seed company headquartered in Guatemala City, Guatemala, for $135 million. Monsanto
expects to consummate the transaction in fourth quarter 2008 with existing cash. The acquisition
will build on Monsantos corn business leadership and enable it to offer farmers in Central America
broader access to high-yielding corn seed varieties.
On June 17, 2008, the board of directors declared a quarterly dividend on its common shares of 24
cents per share. The dividend is payable on July 25, 2008, to shareowners of record on July 3,
2008.
23
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Background
Monsanto Company, along with its subsidiaries, is a leading global provider of agricultural
products for farmers. Our seeds, biotechnology trait products, and herbicides provide farmers with
solutions that improve productivity, reduce the costs of farming, and produce better foods for
consumers and better feed for animals.
We manage our business in two segments: Seeds and Genomics, and Agricultural Productivity. Through
our Seeds and Genomics segment, we produce leading seed brands, including DEKALB, ASGROW, D&PL,
DELTAPINE and SEMINIS, and we develop biotechnology traits that assist farmers in controlling
insects and weeds. We also provide other seed companies with genetic material and biotechnology
traits for their seed brands. Through our Agricultural Productivity segment, we manufacture ROUNDUP
brand herbicides and other herbicides and provide lawn-and-garden herbicide products for the
residential market and animal agricultural products focused on improving dairy cow productivity.
In the fourth quarter of 2007, we sold our U.S. Stoneville® and NexGen® cotton seed brands and
related business assets (divested cotton businesses) as part of the U.S. Department of Justice
(DOJ) approval for the acquisition of Delta and Pine Land Company (DPL). As a result, financial
data for these businesses have been presented as discontinued operations and have been recast and
prepared in compliance with the provisions of Statement of Financial Accounting Standards (SFAS)
No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets (SFAS 144). Accordingly,
the Statements of Consolidated Operations have been conformed to this presentation. The divested
cotton businesses were previously reported as part of the Seeds and Genomics segment. See Note 18
Discontinued Operations for further details.
Managements Discussion and Analysis of Financial Condition and Results of Operations (MD&A) should
be read in conjunction with Monsantos consolidated financial statements and the accompanying
notes. This Report on Form 10-Q should also be read in conjunction with Monsantos Report on Form
10-K for the fiscal year ended Aug. 31, 2007, and Monsantos Report on Form 10-Q for the quarterly
periods ended Nov. 30, 2007, and Feb. 29, 2008. Financial information for the first nine months of
fiscal year 2008 should not be annualized because of the seasonality of our business. The notes to
the consolidated financial statements referred to throughout this MD&A are included in Part I
Item 1 Financial Statements of this Report on Form 10-Q. Unless otherwise indicated,
Monsanto, the company, we, our and us are used interchangeably to refer to Monsanto
Company or to Monsanto Company and its consolidated subsidiaries, as appropriate to the context.
Unless otherwise indicated, earnings (loss) per share and per share mean diluted earnings
(loss) per share. Unless otherwise noted, all amounts and analyses are based on continuing
operations. Unless otherwise indicated, trademarks owned or licensed by Monsanto or its
subsidiaries are shown in all capital letters. Unless otherwise indicated, references to ROUNDUP
herbicides mean ROUNDUP branded herbicides, excluding all lawn-and-garden herbicides, and
references to ROUNDUP and other glyphosate-based herbicides exclude all lawn-and-garden
herbicides.
Non-GAAP Financial Measures
MD&A includes financial information prepared in accordance with U.S. generally accepted accounting
principles (GAAP), as well as two other financial measures, EBIT and free cash flow, that are
considered non-GAAP financial measures. Generally, a non-GAAP financial measure is a numerical
measure of a companys financial performance, financial position or cash flows that exclude (or
include) amounts that are included in (or excluded from) the most directly comparable measure
calculated and presented in accordance with GAAP. The presentation of EBIT and free cash flow
information is intended to supplement investors understanding of our operating performance and
liquidity. Our EBIT and free cash flow measures may not be comparable to other companies EBIT and
free cash flow measures. Furthermore, these measures are not intended to replace net income, cash
flows, financial position, or comprehensive income, as determined in accordance with U.S. GAAP.
24
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
EBIT is defined as earnings (loss) before interest and taxes. Earnings is intended to mean net
income as presented in the Statements of Consolidated Operations under GAAP. EBIT is the primary
operating performance measure for our two business segments. We believe that EBIT is useful to
investors and management to demonstrate the operational profitability of our segments by excluding
interest and taxes, which are generally accounted for across the entire company on a consolidated
basis. EBIT is also one of the measures used by Monsanto management to determine resource
allocations within the company. See Note 17 Segment Information for a reconciliation of EBIT
to net income for the three and nine months ended May 31, 2008, and May 31, 2007.
We also provide information regarding free cash flow, an important liquidity measure for Monsanto.
We define free cash flow as the total of net cash provided or required by operating activities and
provided or required by investing activities. We believe that free cash flow is useful to investors
and management as a measure of the ability of our business to generate cash. This cash can be used
to meet business needs and obligations, to reinvest in the company for future growth, or to return
to our shareowners through dividend payments or share repurchases. Free cash flow is also used by
management as one of the performance measures in determining incentive compensation. See the
Financial Condition, Liquidity, and Capital Resources Cash Flow section of MD&A for a
reconciliation of free cash flow to net cash provided by operating activities and net cash required
by investing activities on the Statements of Consolidated Cash Flows.
Executive Summary
Consolidated Operating Results Net sales increased $746 million in the three-month comparison
and $2,476 million in the nine-month comparison. In third quarter 2008, net sales improved as a
result of higher sales of ROUNDUP and other glyphosate-based herbicides globally, and increased
sales in the United States of soybean seed and traits, corn seed and traits and cotton seed and
traits. In the first nine months of 2008, net sales increased primarily as a result of increased
sales of ROUNDUP and other glyphosate-based herbicides globally combined with higher sales of corn
seed and traits globally, as well as increased sales in the United States of soybean seed and
traits and cotton seed and traits. Net income in third quarter 2008 was $1.45 per share, compared
with $1.03 per share in third quarter 2007. Net income in the first nine months of 2008 was $3.93
per share, compared with $2.17 per share in the prior-year comparable period.
We recorded an after-tax gain of $130 million ($210 million pretax), or $0.23 per share
(Solutia-related gain), associated with the settlement of our claim on Feb. 28, 2008, in connection
with Solutias emergence from bankruptcy. This Solutia-related gain affected our second quarter
2008 and first nine months of 2008 results. See Note 16 Commitments and Contingencies for
further discussion.
Financial Condition, Liquidity, and Capital Resources In the first nine months of 2008, net cash
provided by operating activities was $1,325 million, compared with $89 million in the prior-year
first nine months. This increase was primarily due to improved earnings and a more favorable change
in accounts receivable in the nine-month comparison. The cash received related to our
Solutia-related gain also contributed to this increase. Net cash required by investing activities
was $650 million in the first nine months of 2008, compared with $410 million in the first nine
months of 2007, primarily because of increased capital expenditures. As a result, free cash flow
increased to $675 million in the first nine months of 2008, compared with a negative $321 million
in the first nine months of 2007. For a more detailed discussion of the factors affecting the free
cash flow comparison, see the Cash Flow section of the Financial Condition, Liquidity, and
Capital Resources section in this MD&A.
Outlook We plan to continue to improve our products in order to maintain market leadership and
to support near-term performance. We are focused on applying innovation and technology to make our
farmer customers more productive and profitable by protecting yields and improving the ways they
can produce food, fiber and feed. We use the tools of modern biology to allow farmers to do more
with fewer resources and to produce healthier foods for consumers. Our current research and
development (R&D) strategy and commercial priorities are focused on bringing our farmer customers
second-generation traits, on delivering multiple solutions in one seed (stacking), and on
developing new pipeline products. Our capabilities in biotechnology and breeding research are
generating a rich product pipeline that is expected to drive long-term growth. The commercial
viability of our product pipeline depends in part on the speed of regulatory approvals globally,
and on continued patent and legal rights to offer our products.
We plan to improve and to grow our vegetable and fruit seed business. We are applying our molecular
and marker-assisted breeding capabilities to our library of vegetable and fruit germplasm. Our
purchase of the De Ruiter Seeds business, a leading protected-culture vegetable seeds company, will
allow us to serve our vegetable and fruit seed customers through three
25
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
dedicated platforms: protected-culture, open field and regional vegetable seed businesses. Our
purchase of DPL has expanded our cotton breeding operation. In the future, we will continue to
focus on accelerating the potential growth of these new businesses and executing our business
plans.
ROUNDUP herbicides remain the market leader. We have increased our average selling prices and
experienced increased demand in recent years. We are implementing strategies to meet the future
demand for ROUNDUP. We are focused on managing the costs associated with our agricultural chemistry
business. Our selective acetochlor herbicide products face increasing competitive pressures and a
declining market, in part because of the rapid penetration of ROUNDUP READY corn in the United
States.
See the Outlook section of MD&A for a more detailed discussion of some of the opportunities and
risks we have identified for our business. For additional information related to the outlook for
Monsanto, see Caution Regarding Forward-Looking Statements at the beginning of this Report on
Form 10-Q, Part II Item 1A Risk Factors below and Part I Item 1A of our Report on Form
10-K for the fiscal year ended Aug. 31, 2007.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three
Months Ended May 31, |
|
|
Nine
Months Ended May 31, |
|
|
|
2008 |
|
|
2007 |
|
|
Change |
|
|
2008 |
|
|
2007 |
|
|
Change |
|
|
|
|
Net Sales |
|
$ |
3,588 |
|
|
$ |
2,842 |
|
|
|
26 |
% |
|
$ |
9,466 |
|
|
$ |
6,990 |
|
|
|
35 |
% |
Gross Profit |
|
|
1,969 |
|
|
|
1,503 |
|
|
|
31 |
% |
|
|
5,253 |
|
|
|
3,633 |
|
|
|
45 |
% |
Operating Expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative expenses |
|
|
622 |
|
|
|
487 |
|
|
|
28 |
% |
|
|
1,617 |
|
|
|
1,299 |
|
|
|
24 |
% |
Research and development expenses |
|
|
251 |
|
|
|
190 |
|
|
|
32 |
% |
|
|
672 |
|
|
|
554 |
|
|
|
21 |
% |
Acquired in-process research and development (see Note 3) |
|
|
2 |
|
|
|
7 |
|
|
|
(71 |
)% |
|
|
3 |
|
|
|
7 |
|
|
|
(57 |
)% |
|
|
|
Total Operating Expenses |
|
|
875 |
|
|
|
684 |
|
|
|
28 |
% |
|
|
2,292 |
|
|
|
1,860 |
|
|
|
23 |
% |
|
|
|
Income from Operations |
|
|
1,094 |
|
|
|
819 |
|
|
|
34 |
% |
|
|
2,961 |
|
|
|
1,773 |
|
|
|
67 |
% |
Interest expense |
|
|
31 |
|
|
|
29 |
|
|
|
7 |
% |
|
|
99 |
|
|
|
96 |
|
|
|
3 |
% |
Interest income |
|
|
(34 |
) |
|
|
(28 |
) |
|
|
21 |
% |
|
|
(105 |
) |
|
|
(89 |
) |
|
|
18 |
% |
Solutia-related expense (income) (see Note 16) |
|
|
|
|
|
|
4 |
|
|
NM |
|
|
|
(187 |
) |
|
|
23 |
|
|
NM |
|
Other (income) expense net |
|
|
(5 |
) |
|
|
8 |
|
|
NM |
|
|
|
(2 |
) |
|
|
9 |
|
|
NM |
|
|
|
|
Income from Continuing Operations Before Income Taxes and
Minority Interest |
|
|
1,102 |
|
|
|
806 |
|
|
|
37 |
% |
|
|
3,156 |
|
|
|
1,734 |
|
|
|
82 |
% |
Income tax provision |
|
|
285 |
|
|
|
231 |
|
|
|
23 |
% |
|
|
947 |
|
|
|
521 |
|
|
|
82 |
% |
Minority interest expense |
|
|
6 |
|
|
|
10 |
|
|
|
(40 |
)% |
|
|
13 |
|
|
|
7 |
|
|
|
86 |
% |
|
|
|
Income from Continuing Operations |
|
|
811 |
|
|
|
565 |
|
|
|
44 |
% |
|
|
2,196 |
|
|
|
1,206 |
|
|
|
82 |
% |
|
|
|
Discontinued Operations (see Note 18): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (Loss) from operations of discontinued businesses |
|
|
|
|
|
|
8 |
|
|
NM |
|
|
|
|
|
|
|
(5 |
) |
|
NM |
|
Income tax expense (benefit) |
|
|
|
|
|
|
3 |
|
|
NM |
|
|
|
|
|
|
|
(2 |
) |
|
NM |
|
|
|
|
Income (Loss) on Discontinued Operations |
|
|
|
|
|
|
5 |
|
|
NM |
|
|
|
|
|
|
|
(3 |
) |
|
NM |
|
|
|
|
|
Net Income |
|
$ |
811 |
|
|
$ |
570 |
|
|
|
42 |
% |
|
$ |
2,196 |
|
|
$ |
1,203 |
|
|
|
83 |
% |
|
|
|
Diluted Earnings (Loss) per Share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations |
|
$ |
1.45 |
|
|
$ |
1.02 |
|
|
|
42 |
% |
|
$ |
3.93 |
|
|
$ |
2.18 |
|
|
|
80 |
% |
Income (Loss) on discontinued operations |
|
|
|
|
|
|
0.01 |
|
|
NM |
|
|
|
|
|
|
|
(0.01 |
) |
|
NM |
|
|
|
|
Net Income |
|
$ |
1.45 |
|
|
$ |
1.03 |
|
|
|
41 |
% |
|
$ |
3.93 |
|
|
$ |
2.17 |
|
|
|
81 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NM = Not Meaningful |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective Tax Rate (continuing operations) |
|
|
26 |
% |
|
|
29 |
% |
|
|
|
|
|
|
30 |
% |
|
|
30 |
% |
|
|
|
|
Comparison as a Percent of Net Sales: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit |
|
|
55 |
% |
|
|
53 |
% |
|
|
|
|
|
|
55 |
% |
|
|
52 |
% |
|
|
|
|
Selling, general and administrative expenses |
|
|
17 |
% |
|
|
17 |
% |
|
|
|
|
|
|
17 |
% |
|
|
19 |
% |
|
|
|
|
Research and development expenses (excluding acquired IPR&D) |
|
|
7 |
% |
|
|
7 |
% |
|
|
|
|
|
|
7 |
% |
|
|
8 |
% |
|
|
|
|
Total operating expenses |
|
|
24 |
% |
|
|
24 |
% |
|
|
|
|
|
|
24 |
% |
|
|
27 |
% |
|
|
|
|
Income from continuing operations before income taxes
and minority interest |
|
|
31 |
% |
|
|
28 |
% |
|
|
|
|
|
|
33 |
% |
|
|
25 |
% |
|
|
|
|
Net income |
|
|
23 |
% |
|
|
20 |
% |
|
|
|
|
|
|
23 |
% |
|
|
17 |
% |
|
|
|
|
26
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
Third Quarter Fiscal Year 2008
The following explanations discuss the significant components of our results of operations that
affected the quarter-to-quarter comparison of our third quarter income:
Net sales increased 26 percent in third quarter 2008 from the same quarter a year ago. Our Seeds
and Genomics segment net sales improved 20 percent and our Agricultural Productivity segment net
sales increased 36 percent. The following table presents the percentage changes in third quarter
2008 worldwide net sales by segment compared with net sales in the prior-year quarter, including
the effect volume, price, currency and acquisitions had on these percentage changes:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Third Quarter 2008 Percentage Change in Net Sales vs. Third Quarter 2007 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Impact of |
|
|
|
|
|
|
Volume |
|
|
Price |
|
|
Currency |
|
|
Subtotal |
|
|
Acquisitions(1) |
|
|
Net Change |
|
|
|
|
Seeds and Genomics Segment |
|
|
4 |
% |
|
|
8 |
% |
|
|
2 |
% |
|
|
14 |
% |
|
|
6 |
% |
|
|
20 |
% |
Agricultural Productivity
Segment |
|
|
(2 |
)% |
|
|
31 |
% |
|
|
7 |
% |
|
|
36 |
% |
|
|
|
|
|
|
36 |
% |
Total Monsanto Company |
|
|
1 |
% |
|
|
17 |
% |
|
|
4 |
% |
|
|
22 |
% |
|
|
4 |
% |
|
|
26 |
% |
|
|
|
|
(1) |
|
See Note 3 Business Combinations and Financial Condition, Liquidity, and
Capital Resources in MD&A for details of our acquisitions in fiscal years 2008 and 2007.
Acquisitions are segregated in this presentation for one year from the acquisition date. |
For a more detailed discussion of the factors affecting the net sales comparison, see the Seeds
and Genomics Segment and the Agricultural Productivity Segment sections.
Gross profit increased 31 percent in the three-month comparison. Gross profit as a percent of net
sales (gross profit percentage) for the total company increased 2 percentage points to 55 percent
in third quarter 2008 driven by the increase in ROUNDUP and other glyphosate-based herbicides
average net selling prices. Gross profit percentage in the Seeds and Genomics segment decreased 1
percentage point to 60 percent in third quarter 2008. See the Seeds and Genomics Segment section
of MD&A for details. Gross profit percentage for the Agricultural Productivity segment increased 9
percentage points to 49 percent in third quarter 2008. See the Agricultural Productivity Segment
section of the MD&A for the factors affecting the Agricultural Productivity gross profit.
Operating expenses increased 28 percent, or $191 million, in third quarter 2008 from the prior-year
comparable quarter. In the three-month comparison, selling, general and administrative (SG&A)
expenses increased 28 percent primarily because of the Seeds and Genomics business growth and
acquisitions in the United States and Brazil, and R&D expenses increased 32 percent related to the
increase in our investment in our product pipeline. As a percent of net sales, SG&A expenses and
R&D expenses were 17 percent and 7 percent, respectively, in both three-month periods.
Interest income increased $6 million in the three-month comparison because of interest earned on
higher average cash balances in the United States in third quarter 2008.
Other income net was income of $5 million in third quarter 2008, compared with expense of $8
million in third quarter 2007. Net foreign-currency transaction gains increased $8 million to $4
million in the three-month comparison.
Income tax provision was $285 million in third quarter 2008, compared with $231 million in the
prior-year quarter. The effective tax rate decreased 3 percentage points to 26 percent in the
three-month comparison. Third quarter 2007 included a tax benefit of $34 million primarily as a
result of the conclusion of an IRS audit for tax years 2003 and 2004, and to a lesser extent,
favorable adjustments related to various state income tax matters. The effective tax rate for third
quarter 2008 was affected by a tax benefit of $43 million for the reversal of our remaining net
operating loss valuation allowance in Argentina and additional tax expense for a transfer pricing
item. Without these adjustments, our effective rate for third quarter 2008 would have been even
lower than the 2007 rate, primarily driven by a shift in our projected earnings mix to lower tax
rate jurisdictions.
27
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
First Nine Months of Fiscal Year 2008
The following explanations discuss the significant components of our results of operations that
affected the nine-month comparison of fiscal years 2008 and 2007 income from continuing operations:
Net sales increased 35 percent in first nine months of 2008 from the same period a year ago. Our
Seeds and Genomics segment net sales improved 29 percent and our Agricultural Productivity segment
net sales improved 46 percent. The following table presents the percentage changes in first nine
months of 2008 worldwide net sales by segment compared with net sales in the prior-year first nine
months, including the effect volume, price, currency and acquisitions had on these percentage
changes:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
First Nine Months of 2008 Percentage Change in Net Sales vs. First Nine Months of 2007 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Impact of |
|
|
|
|
|
|
Volume |
|
|
Price |
|
|
Currency |
|
|
Subtotal |
|
|
Acquisitions(1) |
|
|
Net Change |
|
|
|
|
Seeds and Genomics Segment |
|
|
13 |
% |
|
|
8 |
% |
|
|
3 |
% |
|
|
24 |
% |
|
|
5 |
% |
|
|
29 |
% |
Agricultural Productivity
Segment |
|
|
8 |
% |
|
|
30 |
% |
|
|
8 |
% |
|
|
46 |
% |
|
|
|
|
|
|
46 |
% |
Total Monsanto Company |
|
|
11 |
% |
|
|
17 |
% |
|
|
5 |
% |
|
|
33 |
% |
|
|
2 |
% |
|
|
35 |
% |
|
|
|
|
(1) |
|
See Note 3 Business Combinations and Financial Condition, Liquidity, and
Capital Resources in MD&A for details of our acquisitions in fiscal years 2008 and 2007.
Acquisitions are segregated in this presentation for one year from the acquisition date. |
For a more detailed discussion of the factors affecting the net sales comparison, see the Seeds
and Genomics Segment and the Agricultural Productivity Segment sections.
Gross profit increased 45 percent in the nine-month comparison. Gross profit percentage for the
total company increased 3 percentage points to 55 percent in the first nine months of 2008 driven
by the increase in ROUNDUP and other glyphosate-based herbicides average net selling prices. Gross
profit percentage in the Seeds and Genomics segment decreased 1 percentage point to 62 percent in
the first nine months of 2008. See the Seeds and Genomics Segment section of MD&A for details.
Gross profit percentage for the Agricultural Productivity segment increased 12 percentage points to
47 percent in the first nine months of 2008. See the Agricultural Productivity Segment section of
the MD&A for the factors affecting the Agricultural Productivity gross profit.
Operating expenses increased 23 percent, or $432 million, in the first nine months of 2008 from the
prior-year comparable period. In the nine-month comparison, SG&A expenses increased 24 percent and
R&D expenses increased 21 percent primarily because of the Seeds and Genomics business growth and
acquisitions in the United States and Brazil and the increase in our investment in our product
pipeline. As a percent of net sales, SG&A expenses decreased 2 percentage points to 17, and R&D
expenses decreased 1 percentage point to 7 in the nine-month comparison.
Interest income increased $16 million in the nine-month comparison because of interest earned on
higher average cash balances in the United States in the first nine months of 2008.
Solutia-related income was $187 million in first nine months of 2008 compared with Solutia-related
expenses of $23 million in first nine months of 2007. This improvement was a result of our
Solutia-related gain. See Note 16 Commitments and Contingencies for further discussion of
this non-recurring gain.
Other income net was income of $2 million in the first nine months of 2008, compared with
expense of $9 million in the comparable nine-month period of 2007. Net foreign-currency transaction
gains increased $13 million to $1 million in the nine-month comparison.
Income tax provision increased from $521 million in first nine months of 2007 to $947 million in
first nine months of 2008. The effective tax rate was 30 percent in both periods and was impacted
by the following items:
|
|
|
The effective tax rate for first nine months of 2008 was affected by our Solutia-related
gain for which taxes were provided at a higher U.S.-based rate, a tax benefit of $43
million for the reversal of our remaining net operating loss valuation allowance in
Argentina and additional tax expense for a transfer pricing item. |
|
|
|
|
The first nine months of 2007 included several discrete tax adjustments resulting in a
tax benefit of $64 million. The majority of this benefit is the result of audit
settlements, including the conclusion of an IRS audit for tax years 2003
|
28
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
|
|
|
and 2004, an ex-U.S. audit and the resolution of various state income tax matters, and, to a
lesser extent, a benefit related to the retroactive extension of the R&D tax credit that was
enacted as part of the Tax Relief and Health Care Act of 2006 on Dec. 20, 2006. |
Without these items, our effective tax rate for the first nine months of 2008 would have been even
lower than the 2007 rate, primarily driven by a shift in our projected earnings mix to lower tax
rate jurisdictions.
SEEDS
AND GENOMICS SEGMENT
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three
Months Ended May 31, |
|
|
Nine
Months Ended May 31, |
|
(Dollars in millions) |
|
2008 |
|
|
2007 |
|
|
Change |
|
|
2008 |
|
|
2007 |
|
|
Change |
|
|
|
|
Net Sales |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Corn seed and traits |
|
$ |
975 |
|
|
$ |
891 |
|
|
|
9 |
% |
|
$ |
3,189 |
|
|
$ |
2,443 |
|
|
|
31 |
% |
Soybean seed and traits |
|
|
447 |
|
|
|
325 |
|
|
|
38 |
% |
|
|
1,064 |
|
|
|
868 |
|
|
|
23 |
% |
Cotton seed and traits |
|
|
279 |
|
|
|
212 |
|
|
|
32 |
% |
|
|
361 |
|
|
|
260 |
|
|
|
39 |
% |
Vegetable and fruit seed |
|
|
185 |
|
|
|
170 |
|
|
|
9 |
% |
|
|
521 |
|
|
|
444 |
|
|
|
17 |
% |
All other crops seeds and traits |
|
|
161 |
|
|
|
114 |
|
|
|
41 |
% |
|
|
293 |
|
|
|
207 |
|
|
|
42 |
% |
|
|
|
Total Net Sales |
|
$ |
2,047 |
|
|
$ |
1,712 |
|
|
|
20 |
% |
|
$ |
5,428 |
|
|
$ |
4,222 |
|
|
|
29 |
% |
|
|
|
Gross Profit |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Corn seed and traits |
|
$ |
565 |
|
|
$ |
530 |
|
|
|
7 |
% |
|
$ |
2,023 |
|
|
$ |
1,543 |
|
|
|
31 |
% |
Soybean seed and traits |
|
|
269 |
|
|
|
203 |
|
|
|
33 |
% |
|
|
649 |
|
|
|
581 |
|
|
|
12 |
% |
Cotton seed and traits |
|
|
195 |
|
|
|
179 |
|
|
|
9 |
% |
|
|
252 |
|
|
|
222 |
|
|
|
14 |
% |
Vegetable and fruit seed |
|
|
93 |
|
|
|
72 |
|
|
|
29 |
% |
|
|
270 |
|
|
|
210 |
|
|
|
29 |
% |
All other crops seeds and traits |
|
|
97 |
|
|
|
62 |
|
|
|
56 |
% |
|
|
154 |
|
|
|
99 |
|
|
|
56 |
% |
|
|
|
Total
Gross Profit |
|
$ |
1,219 |
|
|
$ |
1,046 |
|
|
|
17 |
% |
|
$ |
3,348 |
|
|
$ |
2,655 |
|
|
|
26 |
% |
|
|
|
EBIT(1) |
|
$ |
586 |
|
|
$ |
557 |
|
|
|
5 |
% |
|
$ |
1,643 |
|
|
$ |
1,302 |
|
|
|
26 |
% |
|
|
|
(1) |
|
EBIT is defined as earnings before interest and taxes. Interest and taxes are
recorded on a total company basis. We do not record these items at the segment level. See Note
17 Segment Information and the Overview Non-GAAP Financial Measures section of MD&A
for further details. |
Seeds and Genomics Financial Performance Third Quarter Fiscal Year 2008
Net sales of corn seed and traits increased 9 percent, or $84 million, in the three-month
comparison primarily because of an increase in sales of U.S. corn seed and traits. In third quarter
2008, our U.S. corn seed and traits sales mix improved because of increased trait penetration,
growth in stacked traits and stronger customer demand in 2008, compared with 2007. Net sales of
corn seed and traits also improved in the Europe-Africa region in the three-month comparison
because of the favorable foreign currency translation rate of the euro.
Net sales of soybean seed and traits increased 38 percent, or $122 million, in the third quarter of
2008, when compared to the third quarter of 2007, primarily because of an increase in sales volume
of U.S. soybean seed and traits driven by stronger customer demand and an increase in soybean acres
in the United States. Net sales of U.S. soybean seed and traits also increased because of higher
average net selling prices.
Net sales of cotton seed and traits increased 32 percent, or $67 million, in the third quarter of
2008, when compared to the third quarter of 2007, primarily because of higher sales of U.S. cotton
seed and traits because of revenues from DPL of $97 million which was not part of the companys
operations during this period last year. This increase in cotton seed and traits revenue was
partially offset by the decrease in cotton trait sales volume resulting from less U.S. cotton acres
in 2008 than in 2007.
All other crops seeds and traits net sales increased 41 percent, or $47 million, in third quarter
2008 primarily because of improved sales of U.S. sugarbeet traits and canola seed and traits in
Canada. Sugarbeet trait volume increased because this product was launched in the United States
during 2008. Sales volume of canola seed and traits improved because of an increase in canola acres
in Canada.
29
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
Gross profit percentage for this segment decreased 1 percentage point in the quarter-over-quarter
comparison to 60 percent. This decline was primarily driven by the decline in the gross profit
percentage in cotton seed and traits. Cotton seed and traits gross profit percentage declined
because of an increase in lower margin cotton seed sales volume as a percentage of total cotton
seed and traits sales. Corn seed and traits gross profit percentage also declined as a result of
the unfavorable impact of a commercial agreement consummated during the third quarter of 2008,
which resolved certain disputes regarding our related corn trait licensing fees.
EBIT for the Seeds and Genomics segment increased $29 million to $586 million in third quarter
2008. The sales increases discussed in this section resulted in $173 million higher gross profit in
third quarter 2008. In the three-month comparison, increased SG&A and R&D expenses related to the
growth in the business and the increase in the investment in R&D partially offset the gross profit
improvement.
Seeds and Genomics Financial Performance First Nine Months of Fiscal Year 2008
Net sales of corn seed and traits increased 31 percent, or $746 million, in the first nine months
of 2008, when compared to the prior year first nine months, primarily because of increased sales of
U.S. corn seed and traits. In the first nine months of 2008, our U.S. corn seed and traits sales
mix and sales volume improved because of increased trait penetration, growth in stacked traits and
stronger customer demand in 2008, compared with 2007. Net sales of corn seed and traits also
improved because of growth in corn seed sales volume in Brazil, Mexico, Argentina and the Asia
Pacific region related to stronger customer demand. Net sales of corn seed in Brazil also improved
because of revenues from a recently acquired subsidiary which was not part of the companys
operations during this period last year. Further, net sales of corn seed and traits increased in
the Europe-Africa region in the nine-month comparison because of higher average selling prices and
the favorable foreign currency translation rate of the euro.
Net sales of soybean seed and traits increased 23 percent, or $196 million, in the first nine
months of 2008, when compared to the prior year first nine months, primarily because of an increase
in sales volume of U.S. soybean seed and traits driven by stronger customer demand and an increase
in soybean acres in the United States. Also, U.S. soybean seed and traits revenues increased
because of higher average net selling prices. Further, net sales of soybean traits increased in
Brazil because of higher average net selling prices.
Net sales of cotton seed and traits increased 39 percent, or $101 million, in the first nine months
of 2008, when compared to the first nine months of 2007, primarily because of higher sales of U.S.
cotton seed and traits because of revenues from DPL of $140 million which was not part of the
companys operations during this period last year. This increase in cotton seed and traits revenue
was partially offset by the decrease in cotton trait sales volume resulting from less U.S. cotton
acres in 2008 than in 2007.
In the first nine months of 2008, vegetable and fruit seed net sales increased 17 percent, or $77
million, in the nine-month comparison primarily because of the favorable foreign currency
translation rate of the euro.
All other crops seeds and traits net sales increased 42 percent, or $86 million, in the first nine
months of 2008, primarily because of improved sales of canola seed and traits, sugarbeet traits,
sunflower seeds and sorghum seeds. Sales volume of canola seed and traits improved because of an
increase in canola acres in Canada. Sugarbeet trait volume increased because this product was
launched in the United States during 2008. Other crops seeds and traits net sales increased because
of favorable foreign currency translation rates, higher prices and improved volumes.
Gross profit percentage for this segment decreased 1 percentage point in the period-over-period
comparison to 62 percent. This decline was primarily driven by the decline in the gross profit
percentage in soybean seed and traits and cotton seed and traits. Soybean seed and traits gross
profit percentage decreased in the first nine months of 2008 because of the unfavorable impact of
higher soybean commodity prices on our cost of production. Cotton seed and traits gross profit
percentage declined because of an increase in lower margin cotton seed sales volume as a percentage
of total cotton seed and traits sales.
EBIT for the Seeds and Genomics segment increased $341 million to $1,643 million in the first nine
months of 2008. The sales increases discussed in this section resulted in $693 million higher gross
profit in the first nine months of 2008. In the nine-month comparison, increased SG&A and R&D
expenses related to the growth in the business and the increase in the investment in R&D partially
offset the gross profit improvement.
30
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
AGRICULTURAL PRODUCTIVITY SEGMENT
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three
Months Ended May 31, |
|
Nine
Months Ended May 31, |
(Dollars in Millions) |
|
2008 |
|
|
2007 |
|
|
Change |
|
|
2008 |
|
|
2007 |
|
|
Change |
|
|
|
|
Net Sales |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ROUNDUP and other glyphosate-based herbicides |
|
$ |
1,168 |
|
|
$ |
757 |
|
|
|
54 |
% |
|
$ |
3,158 |
|
|
$ |
1,936 |
|
|
|
63 |
% |
All other agricultural productivity products |
|
|
373 |
|
|
|
373 |
|
|
|
|
|
|
|
880 |
|
|
|
832 |
|
|
|
6 |
% |
|
|
|
Total Net Sales |
|
$ |
1,541 |
|
|
$ |
1,130 |
|
|
|
36 |
% |
|
$ |
4,038 |
|
|
$ |
2,768 |
|
|
|
46 |
% |
|
|
|
Gross Profit |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ROUNDUP and other glyphosate-based herbicides |
|
$ |
594 |
|
|
$ |
286 |
|
|
|
108 |
% |
|
$ |
1,559 |
|
|
$ |
635 |
|
|
|
146 |
% |
All other agricultural productivity products |
|
|
156 |
|
|
|
171 |
|
|
|
(9 |
)% |
|
|
346 |
|
|
|
343 |
|
|
|
1 |
% |
|
|
|
Total Gross Profit |
|
$ |
750 |
|
|
$ |
457 |
|
|
|
64 |
% |
|
$ |
1,905 |
|
|
$ |
978 |
|
|
|
95 |
% |
|
|
|
EBIT(1) |
|
$ |
502 |
|
|
$ |
242 |
|
|
|
107 |
% |
|
$ |
1,488 |
|
|
$ |
423 |
|
|
|
252 |
% |
|
|
|
|
|
|
(1) |
|
EBIT is defined as earnings before interest and taxes. Interest and taxes are
recorded on a total company basis. We do not record these items at the segment level. See Note
17 Segment Information and the Overview Non-GAAP Financial Measures section of MD&A
for further details. |
Agricultural Productivity Financial Performance Third Quarter Fiscal Year 2008
Net sales of ROUNDUP and other glyphosate-based herbicides increased 54 percent, or $411 million,
in the three-month comparison. In third quarter 2008, net sales of ROUNDUP and other
glyphosate-based herbicides increased globally, especially in Europe, the United States, Asia,
Argentina, Brazil and Canada. The average net selling price increased in all regions. Sales volumes
of ROUNDUP and other glyphosate-based herbicides decreased 7 percent in third quarter 2008 from
third quarter 2007.
Net sales of ROUNDUP and other glyphosate-based herbicides increased globally because of higher
average net selling prices. Further, net sales of ROUNDUP and other glyphosate-based herbicides
increased in Europe and Brazil in the three-month comparison because of the favorable foreign
currency translation rate of the euro and the real, respectively.
The net sales increases discussed throughout this section resulted in $293 million higher gross
profit in third quarter 2008. Gross profit as a percent of sales for the Agricultural Productivity
segment increased 9 percentage points to 49 percent in third quarter 2008 because of higher average
selling prices for ROUNDUP and other glyphosate-based herbicides.
EBIT for the Agricultural Productivity segment increased $260 million to $502 million in third
quarter 2008 because of the increased gross profit discussed in this section.
Agricultural Productivity Financial Performance First Nine Months of Fiscal Year 2008
Net sales of ROUNDUP and other glyphosate-based herbicides increased 63 percent, or $1,222 million,
in the nine-month comparison. In the first nine months of 2008, net sales of ROUNDUP and other
glyphosate-based herbicides increased globally, especially in the United States, Europe, Brazil,
Argentina, Asia and Canada. The average net selling price increased in all regions. Net sales of
ROUNDUP and other glyphosate-based herbicides increased in Europe and Brazil in the nine-month
comparison because of the favorable foreign currency translation rate of the euro and the real,
respectively. Sales volumes of ROUNDUP and other glyphosate-based herbicides increased 8 percent in
the first nine months of 2008 from the first nine months of 2007.
Gross profit percentage for the Agricultural Productivity segment increased 12 percentage points to
47 percent in the first nine months of 2008. This improvement was primarily because of an increase
in the average net selling prices of ROUNDUP and other glyphosate-based herbicides in the first
nine months of 2008, when compared to the first nine months of 2007.
Gross profit increased $927 million because of higher sales of ROUNDUP and other glyphosate-based
herbicides in the first nine months of 2008. EBIT for the Agricultural Productivity segment
increased $1,065 million to $1,488 million in the first
nine months of 2008. Contributing to this increase was our Solutia-related gain recorded in second
quarter 2008. See further discussion at Note 16 Commitments and Contingencies.
31
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
FINANCIAL CONDITION, LIQUIDITY, AND CAPITAL RESOURCES
Working Capital and Financial Condition
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of |
|
|
As of May 31, |
|
Aug. 31, |
(Dollars in millions, except current ratio) |
|
2008 |
|
2007 |
|
2007 |
|
|
|
Cash and cash equivalents |
|
$ |
1,714 |
|
|
$ |
994 |
|
|
$ |
866 |
|
Trade receivables net |
|
|
3,258 |
|
|
|
3,414 |
|
|
|
1,499 |
|
Inventories |
|
|
2,206 |
|
|
|
1,664 |
|
|
|
1,719 |
|
Other current assets(1) |
|
|
949 |
|
|
|
937 |
|
|
|
1,000 |
|
|
|
|
Total Current Assets |
|
$ |
8,127 |
|
|
$ |
7,009 |
|
|
$ |
5,084 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-term debt |
|
$ |
10 |
|
|
$ |
561 |
|
|
$ |
270 |
|
Accounts payable |
|
|
788 |
|
|
|
493 |
|
|
|
649 |
|
Accrued liabilities(2) |
|
|
2,490 |
|
|
|
2,067 |
|
|
|
2,156 |
|
|
|
|
Total Current Liabilities |
|
$ |
3,288 |
|
|
$ |
3,121 |
|
|
$ |
3,075 |
|
|
|
|
Working Capital(3) |
|
$ |
4,839 |
|
|
$ |
3,888 |
|
|
$ |
2,009 |
|
Current Ratio(3) |
|
|
2.47:1 |
|
|
|
2.25:1 |
|
|
|
1.65:1 |
|
|
|
|
|
|
|
(1) |
|
Includes miscellaneous receivables, current deferred tax assets and other current assets. |
|
(2) |
|
Includes income taxes payable, accrued compensation and benefits, accrued marketing
programs, deferred revenues, grower production accruals, dividends payable and miscellaneous
short-term accruals. |
|
(3) |
|
Working capital is total current assets less total current liabilities; current
ratio represents total current assets divided by total current liabilities. |
May 31, 2008, compared with Aug. 31, 2007: Working capital increased $2,830 million between Aug.
31, 2007, and May 31, 2008, because of the favorable effect of foreign currency translation
combined with the following factors:
|
|
|
Cash and cash equivalents increased $848 million between the respective periods. See
the Cash Flow section in this section of MD&A for further details of this increase. |
|
|
|
|
Trade receivables net increased $1,759 million in the first nine months of 2008
primarily because of the seasonality of our sales and collections excluding customer
prepayments, which were classified as accrued liabilities as of May 31, 2008. |
|
|
|
|
Inventories increased $487 million between the respective periods primarily because of
increased corn production to support our market share growth in our global corn business
and the impact of seasonality on our soybean seed business resulting in a higher
inventory balance as of May 31, 2008. Further, our chemistry inventories increased
because of cost increases in certain raw materials required for herbicide production. |
|
|
|
|
Short-term debt decreased $260 million primarily because $238 million 4% Senior Notes
due on May 15, 2008, were classified as short-term debt as of Aug. 31, 2007. See the
Capital Resources and Liquidity section of the MD&A for further discussion of the
retirement of the 4% Senior Notes. |
These increases to working capital between Aug. 31, 2007, and May 31, 2008, were offset primarily
by the following factors:
|
|
|
Accrued liabilities and accounts payable increased $334 million and $139 million,
respectively, primarily because of higher activity levels in 2008 resulting from the
increase in sales and the 2007 acquisitions. Our unrealized losses on foreign currency
hedges also contributed to the increase in accrued liabilities. |
May 31, 2008, compared with May 31, 2007: Working capital increased $951 million between May 31,
2007, and May 31, 2008. The following factors combined with the favorable effect of foreign
currency translation increased working capital as of May 31, 2008, compared with May 31, 2007:
|
|
|
Cash and cash equivalents increased $720 million between the respective periods. See
the Cash Flow section in this section of MD&A and the Cash Flow section of Monsantos
Report on Form 10-K for the fiscal year ended Aug. 31, 2007, for further details of this
increase. |
32
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
|
|
|
Inventories increased $542 million primarily because of increased corn production to
support our market share growth in our global corn business and the impact of higher
commodity prices on our soybean seed business resulting in a higher inventory balance as
of May 31, 2008. Further, our chemistry inventories increased because of cost increases
in certain raw materials required for herbicide production. |
|
|
|
|
Short-term debt decreased $551 million primarily because of the commercial paper
borrowings used to fund our operations as of May 31, 2007. There were no commercial paper
borrowings as of May 31, 2008. Further, short term debt decreased because $238 million of
4% Senior Notes due on May 15, 2008, were classified as short-term debt as of May 31,
2007. See the Capital Resources and Liquidity section of the MD&A for further
discussion of the retirement of the 4% Senior Notes. |
These working capital increases were partially offset primarily by the following factors:
|
|
|
Accrued liabilities and accounts payable increased $423 million and $295 million,
respectively, primarily because of higher activity levels in 2008 resulting from the
increase in sales and the 2007 acquisitions. In addition, deferred revenue increased
related to certain customer prepayments, primarily in the United States. Our unrealized
losses on foreign currency hedges also contributed to the increase in accrued
liabilities. |
Customer Financing Programs: We refer certain of our interested U.S. customers to a third-party
specialty lender that makes loans directly to our customers. We established this revolving
financing program of up to $250 million, which allows certain U.S. customers to finance their
product purchases, royalties and licensing fee obligations. The funding availability may be less
than $250 million if certain program requirements are not met. It also allows us to reduce our
reliance on commercial paper borrowings. Proceeds from customer loans sold through the financing
program totaled $3 million and $6 million for the first nine months of fiscal years 2008 and 2007,
respectively. These proceeds are included in the net cash provided by operating activities in the
Statements of Consolidated Cash Flows. We originate these customer loans on behalf of the
third-party specialty lender, a special purpose entity (SPE) that we consolidate, using our credit
and other underwriting guidelines approved by the lender. We service the loans and provide a
first-loss guarantee of up to $130 million. Following origination, the lender transfers the loans
to multi-seller commercial paper conduits through a nonconsolidated qualifying special purpose
entity (QSPE). We have no ownership interest in the lender, in the QSPE, or in the loans. We
account for this transaction as a sale, in accordance with SFAS No. 140, Accounting for Transfers
and Servicing of Financial Assets and Extinguishment of Liabilities (SFAS 140).
As of May 31, 2008, and Aug. 31, 2007, the customer loans held by the QSPE and the QSPEs liability
to the conduits were $3 million and $301 million, respectively. The lender or the conduits may
restrict or discontinue the facility at any time. If the facility were to terminate, existing loans
would be collected by the QSPE over their remaining terms (generally 12 months or less), and we
would revert to our past practice of providing these customers with direct credit purchase terms.
Our servicing fee revenues from the program were not significant. As of May 31, 2008, and Aug. 31,
2007, our recorded guarantee liability was less than $1 million, primarily based on our historical
collection experience with these customers and a current assessment of credit exposure. Adverse
changes in the actual loss rate would increase the liability.
We entered into an agreement with a lender to establish a program that originally provided
financing of up to $40 million for selected customers in Brazil. The agreement qualified for sales
treatment under SFAS 140. Proceeds from the transfer of the receivables are included in net cash
provided by operating activities in the Statements of Consolidated Cash Flows. Total funds
available under the program have increased to $172 million under subsequent amendments. We received
$107 million and $83 million of proceeds through these customer financing programs in the first
nine months of 2008 and the first nine months of 2007, respectively. The amount of loans
outstanding was $68 million and $86 million as of
May 31, 2008, and Aug. 31, 2007, respectively. The
maximum potential amount of future payments under the guarantees was $68 million as of May 31,
2008. The liability for the guarantee is recorded at an amount that approximates fair value and is
primarily based on our historical collection experience with customers that participate in the
program and a current assessment of credit exposure. Our guarantee liability was $5 million and $3
million as of May 31, 2008, and Aug. 31, 2007, respectively. If performance is required under the
guarantee, we may retain amounts that are subsequently collected from customers.
We also have similar agreements with banks that provide financing to our customers in Brazil
through credit programs that are subsidized by the Brazilian government. In addition, there are
similar financing programs in Europe and Argentina. All of these programs qualify for sales
treatment under SFAS 140. Accordingly, proceeds from the transfer of receivables through the
programs described above are included in net cash provided by operating activities in the
Statements of Consolidated
33
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
Cash Flows. We received $70 million and $81 million of proceeds through these customer financing
programs in the first nine months of 2008 and 2007, respectively. The amount of loans outstanding
was $66 million as of May 31, 2008, and Aug. 31, 2007. For most programs, we provide a full
guarantee of the loans in the event of customer default. The terms of the guarantees are equivalent
to the terms of the bank loans. The maximum potential amount of future payments under the
guarantees was $66 million as of May 31, 2008. The liability for the guarantee is recorded at an
amount that approximates fair value and is primarily based on our historical collection experience
with customers that participate in the program and a current assessment of credit exposure. Our
guarantee liability was $4 million and $2 million as of May 31, 2008, and Aug. 31, 2007,
respectively. If performance is required under the guarantee, we may retain amounts that are
subsequently collected from customers.
We also sell accounts receivable, both with and without recourse. These sales qualify for sales
treatment under SFAS 140 and, accordingly, the proceeds are included in net cash provided by
operating activities in the Statements of Consolidated Cash Flows. The gross amounts of accounts
receivable sold totaled $19 million for the first nine months of 2008 and 2007. The liability for
the guarantees for sales with recourse is recorded at an amount that approximates fair value and is
based on the companys historical collection experience for the customers associated with the sale
of the accounts receivable and a current assessment of credit exposure. Our guarantee liability was
less than $1 million as of May 31, 2008, and Aug. 31, 2007. The maximum potential amount of future
payments under the recourse provisions of the agreements was $16 million as of May 31, 2008. The
outstanding balance of the receivables sold was $16 million and $28 million as of May 31, 2008, and
Aug. 31, 2007, respectively.
Cash Flow
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended May 31, |
(Dollars in millions) |
|
2008 |
|
2007 |
|
Net Cash Provided by Operating Activities |
|
$ |
1,325 |
|
|
$ |
89 |
|
Net Cash Required by Investing Activities |
|
|
(650 |
) |
|
|
(410 |
) |
|
Free Cash Flow(1) |
|
|
675 |
|
|
|
(321 |
) |
|
Net Cash Provided (Required) by Financing Activities |
|
|
93 |
|
|
|
(204 |
) |
Effect of Exchange Rate Changes on Cash and Cash Equivalents |
|
|
80 |
|
|
|
59 |
|
|
Net Increase (Decrease) in Cash and Cash Equivalents |
|
|
848 |
|
|
|
(466 |
) |
Cash and Cash Equivalents at Beginning of Period |
|
|
866 |
|
|
|
1,460 |
|
|
Cash and Cash Equivalents at End of Period |
|
$ |
1,714 |
|
|
$ |
994 |
|
|
|
|
|
(1) |
|
Free cash flow represents the total of net cash provided or required by operating
activities and provided or required by investing activities (see the Non-GAAP Financial
Measures section in MD&A for a further discussion). |
Cash provided by operating activities was $1,325 million in the first nine months of 2008 compared
with $89 million in the first nine months of 2007. This increase was driven by higher earnings and
an increase in cash provided by the change in accounts receivable. The cash received related to our
Solutia-related gain also contributed to this increase. See Note 16 Commitments and
Contingencies for further discussion of this Solutia-related gain.
Cash required by investing activities increased $240 million in the period-over-period comparison.
This increase is primarily because our capital expenditures increased $233 million in the
nine-month comparison to $530 million. The increase in capital expenditures is primarily because of
the expansion of corn seed production facilities. In addition, we used cash of $78 million in the
first nine months of 2008 for the purchase of long-term equity securities. There were no purchases
of long-term equity securities in the first nine months of 2007.
Cash provided by financing activities was $93 million in the first nine months of 2008 compared
with cash required by financing activities of $204 million in the first nine months of 2007. The
net change in short-term financing was a use of cash of $37 million compared with a source of cash
of $257 million in the first nine months of 2008 and 2007, respectively. The net change in
long-term financing was a source of cash of $310 million in the first nine months of 2008 compared
with a use of cash of $273 million.
34
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
Capital Resources and Liquidity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of |
|
|
As of May 31, |
|
Aug. 31, |
(Dollars in millions, except debt-to-capital ratio) |
|
2008 |
|
2007 |
|
2007 |
|
|
|
Short-Term Debt |
|
$ |
10 |
|
|
$ |
561 |
|
|
$ |
270 |
|
Long-Term Debt |
|
|
1,703 |
|
|
|
1,150 |
|
|
|
1,150 |
|
Total Shareowners Equity |
|
|
10,211 |
|
|
|
7,930 |
|
|
|
7,503 |
|
Debt-to-Capital Ratio |
|
|
14% |
|
|
|
18% |
|
|
|
16% |
|
|
|
|
Total debt outstanding increased $293 million between Aug. 31, 2007, and May 31, 2008, primarily
because we issued $550 million of long-term debt and repaid $238 million of short-term debt in
third quarter 2008 as discussed in Note 10 Debt and Other Credit Arrangements. The net proceeds
were used to finance to the expansion of corn seed production facilities.
As discussed in Note 16 Commitments and Contingencies under the subheading Matters related
to Solutia, Inc., Solutia emerged from bankruptcy protection on Feb. 28, 2008, and we received
$163 million in cash from our Solutia-related gain.
Dividend: In June 2008, we declared a quarterly dividend of 24 cents per common share payable on
July 25, 2008, to shareowners of record as of July 3, 2008.
Capital Expenditures: We expect 2008 capital expenditures to be in the range of $950 million
compared with $509 million in 2007. The largest drivers of this increase are expected to be
projects to expand corn seed production facilities and a debottlenecking project at our U.S.
ROUNDUP production facility.
Recently Announced Acquisitions: In March 2008, we entered into a definitive agreement to acquire
100 percent of the outstanding stock of De Ruiter Seeds Group, B.V. and a related company (De
Ruiter). De Ruiter is a leading protected-culture vegetable seeds company based in the Netherlands
with operations worldwide. The purchase price per the agreement was 546 million, which was reduced
by net debt of approximately 53 million or $82 million, resulting in a cash purchase price paid at
closing of 493 million or $769 million. We consummated the transaction with existing cash on June
13, 2008, after receiving approvals from the appropriate regulatory authorities.
In June 2008, we agreed to acquire Marmot, S.A., which operates Semillas Cristiani Burkard, a
privately-held seed company headquartered in Guatemala City, Guatemala, for $135 million. The
acquisition will build on our corn business leadership and enable us to offer farmers in Central
America broader access to high-yielding corn seed varieties. We expect to consummate the
transaction in fourth quarter 2008 with existing cash.
2008 Acquisition: In September 2007, we acquired 100 percent of the outstanding stock of Agroeste
Sementes, a leading Brazilian corn seed company, for approximately $90 million (net of cash
acquired and debt assumed), inclusive of transaction costs of $1 million. Agroeste focuses on
hybrid corn seed production and serves farmers throughout Brazil. We consummated the transaction
with cash. The financial results of this acquisition were included in the companys consolidated
financial statements from the date of acquisition.
2007 Acquisitions: On June 1, 2007, we completed the purchase of all the outstanding stock of DPL
for a cash purchase price of $42 per share, or approximately $1.5 billion (net of cash acquired and
debt assumed), inclusive of transaction costs of $37 million. During 2007, our ASI subsidiary
acquired 10 regional U.S. seed companies in separate transactions for an aggregate purchase price
of $87 million (net of cash acquired), inclusive of transaction costs of $3 million. In conjunction
with one of these acquisitions, we entered into a five-year global technology license agreement.
Also during 2007, we acquired two European vegetable and fruit seed businesses for $61 million,
inclusive of transaction costs of $10 million. Additional contingent purchase price may be payable
in the future if certain earnings targets are met. Such amounts are not expected to be material.
2008 Contractual Obligation: There have been no significant changes to the contractual obligations
table as disclosed in our Annual Report of Form 10-K for the year ended Aug. 31, 2007, except for a
change related to the adoption of Financial Accounting Standards Board (FASB) Interpretation
(FIN) No. 48, Accounting for Uncertainty in Income Taxes an Interpretation of FASB Statement
No. 109 , (FIN 48). The anticipated contractual obligations for unrecognized tax benefits
35
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
under FIN 48 which would require cash settlements were $230 million as of May 31, 2008. Because
there is a high degree of uncertainty regarding the timing of cash flows related to these
unrecognized tax benefit liabilities, we cannot reasonably estimate the settlement periods. The
anticipated contractual obligations for unrecognized tax benefits increased $73 million since the
date of adoption, primarily as a result of the tax consequences of our Solutia-related gain. See
Note 16 Commitments and Contingencies for further discussion of this gain.
Off-Balance Sheet Arrangement
In connection with Solutias plan of reorganization and emergence from bankruptcy, we assumed
financial responsibility for certain litigation and environmental matters for which we had
previously recorded a reserve. As a result, these liabilities are no longer off-balance sheet
arrangements. Our obligation to indemnify Pharmacia for liabilities that Solutia assumed from
Pharmacia in connection with its 1997 spin-off from Pharmacia continues, to the extent that in the
future Solutia fails to pay, perform or discharge those liabilities. See Note 16 Commitments and
Contingencies under the subheading Matters related to Solutia Inc. for further information
regarding Solutia, the liability taken in connection with Solutias Assumed Liabilities, and
Solutias plan of reorganization. Also see Part II Item 1 Legal Proceedings for further
information.
We have achieved an industry-leading position in the areas in which we compete in both of our
business segments. However, the outlook for each part of our business is quite different. In the
Seeds and Genomics segment, our seeds and traits business is expected to expand. In the
Agricultural Productivity segment, our glyphosate business is growing through increases in our
average net selling prices, and our selective chemistry business is expected to decline. As a
result, we are striving to expand our seeds and traits business and working to maintain our
position in our chemistry business.
We believe that our company is positioned to sustain earnings growth and strong cash flow, and we
remain committed to returning value to shareowners through vehicles such as investments that expand
the business, dividends and share repurchases. We will remain focused on cost and cash management
for each segment, both to support the progress we have made in managing our investment in working
capital and to realize the full earnings potential of our businesses. We plan to continue to seek
additional external financing opportunities for our customers as a way to manage receivables for
each of our segments. In 2009, we also expect to see increased gross profit as our higher-margin
seeds and traits business grows and our ROUNDUP average net selling prices improve.
We expect to continue to implement locally responsive business strategies for our businesses in
each world area. Outside of the United States, our businesses will continue to face additional
challenges related to the risks inherent in operating in emerging markets. We have taken steps to
reduce our credit exposure in those areas, which has the potential to affect sales negatively in
the near term.
Seeds and Genomics
Our capabilities in plant breeding and biotechnology research are generating a rich and balanced
product pipeline that we expect will drive long-term growth. We plan to continue to invest in the
areas of seeds, genomics and biotechnology and to invest in technology arrangements that have the
potential to increase the efficiency and effectiveness of our R&D efforts. We believe that our
seeds and traits businesses will have significant near-term growth opportunities through a
combination of improved breeding and continued growth of stacked and second-generation biotech
traits.
We expect advanced breeding techniques combined with improved production practices and capital
investments to continue to contribute to improved germplasm quality and yields for our seed
offerings, leading to increased global demand for both our branded germplasm and our licensed
germplasm. Our vegetable and fruit portfolio will focus on 25 crops. We plan to continue to apply
our molecular breeding and marker capabilities to our vegetable and fruit seed germplasm, and we
expect that to lead to growth in that business. We also plan to continue making strategic
acquisitions by our seed businesses to grow our branded seed market share or expand our germplasm
library and strengthen our global breeding programs. We expect to see continued competition in
seeds and genomics in the near term. We believe we will have a competitive advantage because of our
breeding capabilities and our three-channel sales approach for corn and soybean seeds.
Commercialization of second-generation traits and the stacking of multiple traits in corn and
cotton are expected to increase penetration in approved markets, particularly as we continue to
price our traits in line with the value growers have
36
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
experienced. In 2008, we expect that higher-value, stacked-trait products will represent a larger
share of our total U.S. corn seed sales than they did in 2007. Acquisitions may also present
near-term opportunities to increase penetration of our traits. In particular, we expect that our
acquisition of DPL will enable us to accelerate penetration of our second-generation cotton traits
in 2009 and later years. We expect the competition in biotechnology to increase, as more
competitors launch traits in the United States and internationally by the end of the decade.
However, we believe we will have a competitive advantage because we will be poised to deliver
second- and third-generation traits when our competitors are delivering their first-generation
traits.
Regulatory approvals have been obtained in the United States, Canada, and various importing
countries for ROUNDUP READY 2 YIELD soybeans, our second-generation glyphosate-tolerant soybean
product that is expected to have a limited launch in 2009. In addition, regulatory submissions and
reviews for ROUNDUP READY 2 YIELD are proceeding in other key soybean-importing countries.
Significant progress has also been made for our second generation stacked Bt corn product,
YIELDGARD VT TRIPLE PRO. The U.S. Environmental Protection Agency granted registration for
YIELDGARD VT TRIPLE PRO with a reduced corn borer refuge requirement for the dual Bt
gene-containing product to 20 percent in the southern cotton growing areas from the current 50
percent requirement for single Bt gene corn borer products. In addition, we have submitted an
amendment to the EPA for YIELDGARD VT TRIPLE PRO requesting a refuge reduction from 20 percent to 5
percent in the Corn Belt for corn borers. In Canada YIELDGARD VT PRO was granted food, feed, and
environmental release approval from Health Canada and the Canadian Food Inspection Agency (CFIA),
respectively. The CFIA was the first agency to grant commercialization approval for YIELDGARD VT
PRO with a reduced 5 percent refuge requirement for corn borers. Regulatory submissions have also
been initiated for SMARTSTAX corn including a request to the EPA for a 5 percent refuge in the Corn
Belt for this dual Bt gene product which will control above and below ground pests and is
anticipated to launch in the United States in 2010. Global cultivation opportunities were expanded
for corn, with Argentina and South Africas regulatory approvals for YIELDGARD Corn Borer stacked
with ROUNDUP READY Corn 2 in 2007, and with Brazils recent approval for YIELDGARD Corn Borer.
YIELDGARD Corn Borer is our first biotech corn product to be commercialized in Brazil.
During 2007, we and BASF announced a long-term joint research and development and commercialization
collaboration in plant biotechnology that will focus on high-yielding crops and crops that are
tolerant to adverse conditions such as drought. Over the long-term life of the collaboration, we
and BASF will dedicate a joint budget of potentially $1.5 billion to fund a dedicated pipeline of
yield and stress tolerance traits for corn, soybeans, cotton and canola.
Our international traits businesses, in particular, will probably continue to face unpredictable
regulatory environments that may be highly politicized. We operate in volatile, and often
difficult, economic environments. Although we see growth potential in our India cotton business
with the ongoing conversion to new hybrids and BOLLGARD II, this business is currently operating
under state governmental pricing directives that we believe limit near-term earnings growth.
In Brazil, we expect to continue to operate our dual-track business model of certified seeds and
our point-of-delivery payment system to ensure that we capture value on all Monsanto ROUNDUP READY
soybeans and BOLLGARD cotton crops grown there. Income is expected to grow as farmers choose to
plant more of these approved traits. However, full regulatory system approval of additional traits
must be realized for us to see a step change in contributions from seeds and traits. As noted
above, YIELDGARD Corn Borer corn was approved recently. The agricultural economy in Brazil is
benefiting from strong global commodity prices, particularly for corn and soybeans. Although farmer
liquidity has improved from last year, we continue to monitor our credit policy, expand our
grain-based collection system, and increase cash sales, as part of a continuous effort to manage
our Brazilian risk against possible market and foreign exchange volatility.
It is likely that rulings of patent infringement from several ongoing court cases in Europe will be
required before we can expect to capture value from our ROUNDUP READY soybeans grown in Argentina.
One Spanish case and a U.K. case have had adverse early results and are being appealed. The first
case in Holland has now been referred to the European Court of Justice (ECJ) for an
interpretation of the EU patent law for biotech products. This will probably take up to two years.
It is likely that all other cases on continental Europe will await the outcome of the ECJ ruling.
We are continuing to discuss alternative arrangements with various stakeholders. However, we have
no certainty that any of these discussions will lead to an income producing outcome in the near
term. We do not plan to commercialize new soybean or cotton traits in Argentina until we can
achieve more certainty that we would be compensated for the technology.
In March 2008, a judge of the French Supreme Administrative court (Conseil dEtat) rejected an
application for interim relief by French farmers, French grower associations and various companies
including us to overturn the French governments
37
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
suspension of planting of YIELDGARD Corn Borer pending review and completion under a new regulatory
regime. The outcome means that there will be no sales and planting of this product in France during
the forthcoming growing season. The legality of the suspension will be decided after a full hearing
before the court later this year.
Agricultural Productivity
We believe our ROUNDUP herbicide business will continue to generate a sustainable source of cash
and gross profit. Pricing of generic formulations of glyphosate herbicides has increased during
2008. The generic and private-label pricing can be somewhat unstable during the short-term, but we
believe both the short- and long-term trends will be favorable relative to the previous three year
period. We have experienced increased demand in recent years, and we are implementing strategies to
meet the future demands for ROUNDUP, as well as for our glyphosate supply business. To sustain the
cash and income generation of our ROUNDUP business, we will continue to actively manage our
inventory and other costs and offer product innovations, superior customer service and logistics
and marketing programs to support or allow us to maintain premium prices commensurate with our
brands value. Further expansion of crops with our ROUNDUP READY traits may also incrementally
increase sales of our ROUNDUP products.
Like most other selective herbicides, our selective acetochlor herbicide products face increasing
competitive pressures and a declining market, in part because of the rapid penetration of ROUNDUP
READY corn in the United States. We will continue to seek ways to optimize our selective herbicides
business, as we believe it is important to offer fully integrated crop-protection solutions,
particularly in ROUNDUP READY corn. We anticipate a continued decline in this business in the near
term, but the gross profit from the ROUNDUP READY traits and from the ROUNDUP herbicides used on
these acres are significantly higher than the gross profit from the lost selective herbicide sales.
We expect that our lawn-and-garden herbicide products will remain a strong cash generator and
support our ROUNDUP brand equity in the marketplace. However, we anticipate continued competition
from generic and private-label products and, as a result, sales price pressures from major
retailers.
Our contract with Sandoz GmbH, which manufactured the active ingredient and the finished dose
formulation for POSILAC has been terminated with production ending in May 2008. We have planned for
this contract termination and have a secure supply and sufficient capacity at our FDA approved
facility in Augusta, Georgia. We believe some
processor requests for milk produced by cows not supplemented with rbST will limit our future
sales.
Other Information
As discussed in Note 16 Commitments and Contingencies and Part II Item 1 Legal
Proceedings, Monsanto is involved in a number of lawsuits and claims relating to a variety of
issues. Many of these lawsuits relate to intellectual property disputes. We expect that such
disputes will continue to occur as the agricultural biotechnology industry evolves. Third parties,
including non-governmental organizations, have challenged the validity or enforceability of patents
issued to the company regarding our biotechnology products. For additional information related to
the outlook for Monsanto, see Caution Regarding Forward-Looking Statements at the beginning of
this Report on Form 10-Q, Part II Item 1A Risk Factors below and Part I Item 1A of our
Report on Form 10-K for the fiscal year ended Aug. 31, 2007.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
In preparing our financial statements, we must select and apply various accounting policies. Our
most significant policies are described in Part II Item 8 Note 2 Significant Accounting
Policies to the consolidated financial statements contained in our Report on Form 10-K for the
fiscal year ended Aug. 31, 2007. In order to apply our accounting policies, we often need to make
estimates based on judgments about future events. In making such estimates, we rely on historical
experience, market and other conditions, and on assumptions that we believe to be reasonable.
However, by its nature the estimation process is uncertain, given that estimates depend on events
over which we may not have control. If market and other conditions change from those that we
anticipate, our financial condition, results of operations, or liquidity may be affected
materially. In addition, if our assumptions change, we may need to revise our estimates or take
other corrective actions, either of which may have a material effect on our financial condition,
results of operations, or liquidity.
38
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
Based on the significance of our amortizable intangible assets and in particular, those associated
with biotechnology, we have added a significant accounting policy related to our accounting for
intangible assets since our Report on Form 10-K for the fiscal year ended Aug. 31, 2007. In
accordance with SFAS 144, all amortizable intangible assets are assessed for impairment whenever
events indicate a possible loss. Such an assessment involves estimating undiscounted cash flows
over the remaining useful life of the intangible. If the review indicates that undiscounted cash
flows are less than the recorded value of the intangible asset, the carrying amount of the
intangible is reduced by the estimated cash-flow shortfall on a discounted basis, and a
corresponding loss is charged to the Statement of Consolidated Operations. Significant changes in
key assumptions about the business, market conditions and prospects for which the intangible asset
is currently utilized or expected to be utilized, could result in an impairment charge.
The estimates that have a higher degree of inherent uncertainty and require our most significant
judgments are outlined in Managements Discussion and Analysis of Financial Condition and Results
of Operations contained in our Report on Form 10-K for fiscal year ended Aug. 31, 2007. Had we used
estimates different from any of those contained in such Report on Form 10-K, our financial
condition, profitability, or liquidity for the current period could have been materially different
from those presented in this Form 10-Q.
In May 2008, the FASB issued SFAS No. 162, The Hierarchy of Generally Accepted Accounting
Principles (SFAS 162). SFAS 162 identifies the sources of accounting principles and the framework
for selecting principles to be used in the preparation and presentation of financial statements in
accordance with generally accepted accounting principles. This statement will be effective 60 days
after the Securities and Exchange Commission approves the Public Company Accounting Oversight
Boards amendments to AU Section 411, The Meaning of Present Fairly in Conformity With Generally
Accepted Accounting Principles. We do not anticipate the adoption of SFAS 162 will have an effect
on the consolidated financial statements.
In March 2008, the FASB issued SFAS No. 161, Disclosures about Derivative Instruments and Hedging
Activities (SFAS 161). SFAS 161 amends and expands the disclosure requirements of SFAS 133,
Accounting for Derivative Instruments and Hedging Activities (SFAS 133). It requires qualitative
disclosures about objectives and strategies for using derivatives, quantitative disclosures about
fair value amounts of gains and losses on derivative instruments, and disclosures about
credit-risk-related contingent features in derivative agreements. This statement is effective for
financial statements issued for fiscal years beginning after Nov. 15, 2008. Accordingly, we will
adopt SFAS 161 in second quarter 2009. We are currently evaluating the impact of SFAS 161 on the
consolidated financial statements.
In December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests in Consolidated Financial
Statements an amendment of ARB No. 51 (SFAS 160). SFAS 160 requires an entity to clearly
identify and present ownership interests in subsidiaries held by parties other than the entity in
the consolidated financial statements within the equity section but separate from the entitys
equity. It also requires the amount of consolidated net income attributable to the parent and to
the noncontrolling interest be clearly identified and presented on the face of the consolidated
statement of income; changes in ownership interest be accounted for similarly, as equity
transactions; and when a subsidiary is deconsolidated, any retained noncontrolling equity
investment in the former subsidiary and the gain or loss on the deconsolidation of the subsidiary
be measured at fair value. This statement is effective for financial statements issued for fiscal
years beginning after Dec. 15, 2008. Accordingly, we will adopt SFAS 160 in fiscal year 2010. We
are currently evaluating the impact of SFAS 160 on the consolidated financial statements.
In December 2007, the FASB issued SFAS No. 141 (revised 2007), Business Combinations (SFAS 141R).
Under SFAS 141R, an entity is required to recognize the assets acquired, liabilities assumed,
contractual contingencies and contingent consideration measured at their fair value at the
acquisition date. It further requires that acquisition-related costs are to be recognized
separately from the acquisition and expensed as incurred. In addition, acquired in-process research
and development (IPR&D) is capitalized as an intangible asset and amortized over its estimated
useful life. The IPR&D is evaluated for impairment and if no alternative future use exists, the
asset is expensed. SFAS 141R is effective for business combinations for which the acquisition date
is after the beginning of the first annual reporting period beginning after Dec. 15, 2008.
Accordingly, we will adopt SFAS 141R in fiscal year 2010. We are currenty evaluating the impact of SFAS 141R on the
consolidated financial statements.
39
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
In February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial Assets and
Financial Liabilities (SFAS 159). SFAS 159 permits entities to choose to measure many financial
instruments and certain other items at fair value. The objective is to improve financial reporting
by providing entities with the opportunity to mitigate volatility in reported earnings caused by
measuring related assets and liabilities using different measurement techniques. SFAS 159 requires
additional disclosures related to the fair value measurements included in the entitys financial
statements. This statement is effective for financial statements issued for fiscal years beginning
after Nov. 15, 2007. Accordingly, we will adopt SFAS 159 in fiscal year 2009. We are currently
evaluating the impact of SFAS 159 on the consolidated financial statements.
In September 2006, the FASB issued SFAS No. 157, Fair Value Measurement (SFAS 157). SFAS 157
defines fair value, establishes a framework for measuring fair value in generally accepted
accounting principles, and expands disclosures about fair value measurements. This statement is
effective for financial statements issued for fiscal years beginning after Nov. 15, 2007.
Accordingly, we will adopt SFAS 157 in fiscal year 2009. We are currently evaluating the impact of
adopting SFAS 157 on the consolidated financial statements.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
There are no material changes related to market risk from the disclosures in Monsantos Report on
Form 10-K for the fiscal year ended Aug. 31, 2007.
ITEM 4. CONTROLS AND PROCEDURES
We maintain a comprehensive set of disclosure controls and procedures (as defined in Rules
13a-15(e) and 15d-15(e) under the Exchange Act) designed to ensure that information required to be
disclosed in our filings under the Exchange Act is recorded, processed, summarized and reported
accurately and within the time periods specified in the SECs rules and forms. As of May 31, 2008
(the Evaluation Date), an evaluation was carried out under the supervision and with the
participation of our management, including our Chief Executive Officer and Chief Financial Officer,
of the effectiveness of the design and operation of our disclosure controls and procedures. Based
upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of
the Evaluation Date, the design and operation of these disclosure controls and procedures were
effective to provide reasonable assurance of the achievement of the objectives described above.
During the quarter that ended on the Evaluation Date, there was no change in internal control over
financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that has
materially affected, or is reasonably likely to materially affect, our internal control over
financial reporting.
PART IIOTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
We are involved in various legal proceedings that arise in the ordinary course of our business, as
well as proceedings that we have considered to be material under SEC regulations. These include
proceedings to which we are party in our own name and proceedings to which Pharmacia or Solutia is
a party but that we manage and for which we are responsible. We believe we have meritorious legal
arguments and will continue to represent our interests vigorously in all of the proceedings that we
are defending or prosecuting. Information regarding certain material proceedings and the possible
effects on our business of proceedings we are defending is disclosed in Note 16 Commitments and
Contingencies under the subheading Litigation and Indemnification and is incorporated by
reference herein. Following is information regarding other potentially material proceedings for
which we are responsible.
The following discussion provides new and updated information regarding certain proceedings for
which we are responsible. Other information with respect to legal proceedings appears in our Report
on Form 10-K for the fiscal year ended Aug. 31, 2007, and our Reports on Form 10-Q for the
quarterly periods ended Nov. 30, 2007, and Feb. 29, 2008.
40
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
Patent and Commercial Proceedings
As described in Monsantos Report on Form 10-K for the fiscal year ended Aug. 31, 2007, and on Form
10-Q for the quarterly period ended Feb. 29, 2008, on Dec. 4, 2000, we filed suit in the U.S.
District Court for the Eastern District of Missouri for a declaratory judgment against Bayer
CropScience AG, a subsidiary of Bayer AG, and its affiliates that four patents that involve claims
to truncated Bt technology were invalid and not infringed by the MON810 corn product contained in
YIELDGARD corn. Bayer CropScience counterclaimed to request royalties for prior sales of YIELDGARD
corn and injunctive relief but later dismissed with prejudice its claims on three of the four
patents in dispute and agreed not to sue us, our affiliates or our sublicensees under those patents
for any of our current commercial products. On Nov. 22, 2005, a jury returned a verdict in our
favor and determined that MON810 did not infringe the remaining patent at issue and that the patent
was invalid. On Aug. 28, 2006, the Court entered an order also invalidating the patents on the
basis of inequitable conduct. On Jan. 25, 2008, the U.S. Court of Appeals for the Federal Circuit
affirmed the judgment of the district court that Bayer CropSciences patents were invalid on the
basis of inequitable conduct. On May 14, 2008, the Federal Circuit affirmed a judgment awarding
Monsanto its attorney fees and costs of appeal.
On May 23, 2008, we announced a global business agreement with Syngenta AG (Syngenta) that
establishes business arrangements including commercial licensing agreements and the dismissal of
all patent, antitrust and commercial litigation between the companies, including the following
matters:
|
|
|
As described in Monsantos Report on Form 10-K for the fiscal year ended Aug. 31, 2007,
and on Form 10-Q for the quarterly period ended Feb. 29, 2008, on May 10, 2004, we filed
suit against Syngenta Seeds in the Circuit Court of St. Louis County, Missouri, for a
declaratory judgment seeking a determination that, under its license from us, Syngenta
Seeds is limited to commercializing its ROUNDUP READY soybeans under one product brand. On
Feb. 8, 2006, after a bench trial, the Court ruled in our favor and permanently enjoined
Syngenta from using any brand other than the NK® brand in the production, marketing,
advertising, or sale of our ROUNDUP READY soybean technology. On June 12, 2007, the
Missouri Court of Appeals reversed the judgment of the trial court and remanded for a new
trial. |
|
|
|
|
As described in our Report on Form 10-K for the fiscal year ended Aug. 31, 2007, on May
12, 2004, we filed suit against Syngenta Seeds and Syngenta Biotechnology, Inc. in the U.S.
District Court for the District of Delaware (the Shah case). On July 27, 2004, DEKALB filed
suit against Syngenta Seeds and Syngenta Biotechnology in the U.S. District Court for the
Northern District of Illinois (the Lundquist case). The suits alleged infringement of our
patents involving glyphosate-tolerant crops and fertile transgenic corn and seek
injunctions against the sale of GA21 corn by Syngenta and its affiliates and damages for
willful infringement of our patents. On May 19, 2005, the U.S. District Court for the
Northern District of Illinois transferred the Lundquist case to the U.S. District Court for
the District of Delaware. It was then consolidated for discovery and trial with the Shah
case. The District Court granted summary judgment in favor of Syngenta on May 11, 2006,
ruling that the Shah patent was invalid and Syngenta did not infringe the Lundquist
patents. On June 8, 2006, we appealed the Courts decision to the U.S. Court of Appeals for
the Federal Circuit. On Oct. 4. 2007, the Federal Circuit affirmed the decision of the
District Court. |
|
|
|
|
As described in our Report on Form 10-K for the fiscal year ended Aug. 31, 2007, and on
Form 10-Q for the quarterly period ended Nov. 30, 2007, on July 28, 2004, Syngenta filed
suit against us in the U.S. District Court for the District of Delaware, alleging that we
have monopolized or attempted to monopolize markets for glyphosate-tolerant corn seed,
European corn borer-protected corn seed and foundation corn seed (the Antitrust Action).
Syngenta sought $57 million in supposed actual damages and requested treble damages,
attorneys fees and injunctive relief. In July 2005, we filed counterclaims against
Syngenta, Syngenta Seeds, and affiliated companies for misappropriation of property and
false advertising. |
|
|
|
|
As described in our Report on Form 10-K for the fiscal year ended Aug. 31, 2007, and on
Form 10-Q for the quarterly period ended Nov. 30, 2007, on Sept. 21, 2004, Golden Harvest
Seeds, Inc., a subsidiary of Syngenta, filed suit against us in the Circuit Court of St.
Louis County, Missouri, seeking a declaration with respect to its right to sell-off certain
corn products after the termination of its various corn trait licenses with us. We
counterclaimed for unjust enrichment and breach of the agreements and seek recovery of
damages and injunctive relief. |
|
|
|
|
As described in our Report on Form 10-K for the fiscal year ended Aug. 31, 2007, on Aug.
7, 2006, acting on a long pending jury advisory verdict, the U.S. District Court for the
Middle District of North Carolina ruled that scientists
of Rhône Poulenc Agrochimie S.A. were entitled to be named as co-inventors of U.S. Patent
No. 6,040,497 but were not entitled to be named as co-inventors of U.S. Patent No. 5,554,798
(the 798 Patent). The 798 Patent covers |
41
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
|
|
|
glyphosate-tolerant crops and fertile transgenic corn and was assigned to DEKALB. On Aug. 9,
2006, DEKALB filed suit against Syngenta Seeds and Syngenta Biotechnology in the U.S.
District Court for the Eastern District of Missouri. The suit alleged infringement of the
798 Patent by the making and selling of GA21 corn. |
As described in our Report on Form 10-K for the fiscal year ended Aug. 31, 2007, on July 26, 2005,
and on Form 10-Q for the quarterly period ended Feb. 29, 2008, American Seed Company (which is
unrelated to Monsanto or its ASI subsidiary) filed a purported class action suit against us in the
U.S. District Court for the District of Delaware, supposedly on behalf of direct purchasers of corn
seed containing our transgenic traits. American Seed essentially alleges that we have monopolized
or attempted to monopolize markets for glyphosate-tolerant corn seed, European corn borer-protected
corn seed and foundation corn seed. Plaintiffs seek an unspecified amount of damages and injunctive
relief. On Nov. 13, 2006, the trial court denied plaintiffs motion for class certification. On
April 1, 2008, the U. S. Court of Appeals for the Third Circuit affirmed the trial courts decision
denying class certification. On May 12, 2008, the Third Circuit denied plaintiffs motion for
rehearing en banc.
As described in our Report on Form 10-K for the fiscal year ended Aug. 31, 2007, starting the week
of March 7, 2004, a series of purported class action cases were filed in 14 different state courts
against Pioneer Hi-Bred International, Inc. and us. The suits allege that we conspired with Pioneer
to violate various state competition and consumer protection laws by allegedly fixing and
artificially inflating the prices and fees for our various biotechnology traits and seeds
containing those traits and imposing certain use restrictions. All of these cases have been
transferred to the U.S. District Court for the Eastern District of Missouri and consolidated,
except for one case that was pending in state court in Tennessee, which has been dismissed. On May
27, 2008 the Court entered a Scheduling Order setting dates for class related discovery and
requiring the plaintiffs to file their motion for class certification by April 30, 2009. No date is
set for the class certification hearing.
Two purported class action suits were filed against us on Sept. 26, 2006, supposedly on behalf of
all farmers who purchased our Roundup brand herbicides in the United States for commercial
agricultural purposes since Sept. 26, 2002. Plaintiffs essentially allege that we have monopolized
the market for glyphosate for commercial agricultural purposes, and seek an unspecified amount of
damages and injunctive relief. In late February 2007, three additional suits were filed, alleging
similar claims. All of these suits were filed in the U.S. District Court for the District of
Delaware. On July 18, 2007, the court ruled that any such suit had to be filed in federal or state
court in Missouri and granted our motion to dismiss the two original cases. On Aug. 8, 2007,
plaintiffs in the remaining three cases voluntarily dismissed their complaints, which have not been
re-filed. On Aug. 10, 2007, the same set of counsel filed a parallel action in federal court in San
Antonio, Texas, on behalf of a retailer of glyphosate named Texas Grain. Plaintiffs seek to certify
a national class of all entities that purchased glyphosate directly from us since August 2003. The
Court has set a hearing to determine if the case should proceed as a class action for Feb. 11,
2009.
Agent Orange Proceedings
As described in Monsantos Report on Form 10-K for the fiscal year ended Aug. 31, 2007, and on Form
10-Q for the quarterly period ended Feb. 29, 2008, various manufacturers of herbicides used by the
U.S. armed services during the Vietnam War, including the former Monsanto Company, have been
parties to lawsuits filed on behalf of veterans and others alleging injury from exposure to the
herbicides. In re Agent Orange Product Liability Litigation, MDL 381 (MDL), a multidistrict
litigation proceeding established in 1977 to coordinate Agent Orange-related litigation in the
United States, was settled in 1984, concluding all class action litigation filed on behalf of U.S.
and certain other groups of plaintiffs. After the U.S. Supreme Court allowed new claims to proceed
notwithstanding the settlement, this litigation was sent back to Judge Weinstein of the U.S.
District Court for the Eastern District of New York, who originally presided over the MDL. After a
hearing during the week of Feb. 28, 2005, the District Court granted the motions for summary
judgment filed by Monsanto and other defendants in all pending cases arising out of claims from
U.S. veterans on the basis of the government contractor defense. On Feb. 22, 2008, U.S. Court of
Appeals for the Second Circuit affirmed the judgment of the district court and on May 7, 2008 the
Court denied plaintiffs motion for rehearing.
As described in Monsantos Report on Form 10-K for the fiscal year ended Aug. 31, 2007, and on Form
10-Q for the quarterly period ended Feb. 29, 2008, a purported class action suit, styled VAVAO, et
al. v. The Dow Chemical Company, et al., was filed in the U.S. District Court for the Eastern
District of New York by the Vietnam Association of Victims of Agent Orange (VAVAO) alleging that
the manufacturers of Agent Orange conspired with the U.S. government to commit war crimes and
crimes against humanity in connection with the spraying of Agent Orange. This case was also
assigned to Judge Weinstein. On March 10, 2005, the District Court granted the motions to dismiss
and for summary judgment filed by
42
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
Monsanto and other defendants in this case. On Feb. 22, 2008, U.S. Court of Appeals for the Second
Circuit affirmed the judgment of the district court and on
May 7, 2008, the Court denied plaintiffs
motion for rehearing.
As described in Monsantos Report on Form 10-K for the fiscal year ended Aug. 31, 2007, and on Form
10-Q for the quarterly period ended Feb. 29, 2008, in a purported class action suit styled Dobbie,
et al. v. The Attorney General of Canada, pending in the Federal Court of Canada in Ottawa, Canada,
individuals who either served at or live by a Canadian Forces Base in Gagetown, New Brunswick,
brought an action against the Canadian government for injuries supposedly suffered as the result of
exposure to a variety of chemicals used by it during the course of a 30-year program to control
weeds and vegetation at the facility. After Dow Chemical and Monsanto were joined as third-parties
to the federal action, the Court on June 10, 2008 discontinued the action for lack of jurisdiction.
Purported class action lawsuits have been filed by plaintiffs against the Canadian government in
eight provinces, with Monsanto and Dow being joined as third-party defendants in the Newfoundland
and New Brunswick actions. Those third-party actions by the Canadian government join Dow and us as
manufacturers of Agent Orange and seek contribution and indemnification for any injuries plaintiffs
may have suffered as the result of the spraying of Agent Orange and other chemicals in 1966 and
1967. On Aug. 1, 2007, the trial court in the case pending in Newfoundland certified a class of all
individuals who were at CFB Gagetown between 1956 and the present and who claim they were exposed
to dangerous levels of dioxin or HCB while on the base. On Sept. 18, 2007, the Newfoundland Court
of Appeal granted the application of the Canadian government, Dow, and Monsanto for leave to appeal
the trial courts class certification decision.
Please see Caution Regarding Forward-Looking Statements, at the front of this Report on Form 10-Q
and Part I Item 1A Risk Factors of our Report on Form 10-K for the fiscal year ended Aug.
31, 2007, and Part II Item 1A Risk Factors of our Report on Form 10-Q for the quarter ended
Feb. 29, 2008, for information regarding risk factors. There have been no material changes from the
risk factors previously disclosed.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Issuer Purchases of Equity Securities
The following table is a summary of any purchases of equity securities during the third quarter of
fiscal year 2008 by Monsanto and any affiliated purchasers, pursuant to SEC rules.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(c) Total Number of |
|
|
(d) Approximate Dollar |
|
|
|
|
|
|
|
|
|
|
|
Shares Purchased as |
|
|
Value of Shares that May |
|
|
|
|
|
|
|
|
|
|
|
Part of Publicly |
|
|
Yet Be Purchased |
|
|
|
(a) Total Number of |
|
|
(b) Average Price Paid |
|
|
Announced Plans or |
|
|
Under the Plans or |
|
Period |
|
Shares Purchased |
|
|
per Share(1) |
|
|
Programs |
|
|
Programs |
|
|
March 2008: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Mar. 1, 2008, through Mar. 31, 2008 |
|
|
109,183 |
|
|
|
$ 109.24 |
|
|
|
109,183 |
|
|
|
$ 358,740,073 |
|
April 2008: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Apr. 1, 2008, through Apr. 30, 2008 |
|
|
6,924 |
(2) |
|
|
$ 112.14 |
|
|
|
5,226 |
|
|
|
$ 1,158,167,002 |
|
May 2008: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
May 1, 2008, through May 31, 2008 |
|
|
102,763 |
|
|
|
$ 121.64 |
|
|
|
102,763 |
|
|
|
$ 1,145,666,938 |
|
|
Total |
|
|
218,870 |
|
|
|
$ 115.15 |
|
|
|
217,172 |
|
|
|
$ 1,145,666,938 |
|
|
|
|
|
(1) |
|
The average price paid per share is calculated on a settlement basis and excludes
commission. |
|
(2) |
|
Includes 1,698 shares withheld to cover the withholding taxes upon the vesting of
restricted stock. |
On Oct. 25, 2005, the board of directors authorized the purchase of up to $800 million of the
companys common stock over a four-year period. The plan expires on Oct. 25, 2009. On April 16,
2008, the board of directors authorized a new share repurchase program of up to $800 million of the
companys common stock over a three-year period. This repurchase program will commence at the time
the companys current share repurchase program is completed or Oct. 25, 2009, whichever is earlier.
The plan expires on April 16, 2011. There were no other publicly announced plans outstanding as of
May 31, 2008.
43
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
Exhibits: The list of exhibits in the Exhibit Index to this Report is incorporated herein by
reference.
44
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
MONSANTO COMPANY
(Registrant)
|
|
|
By: |
/s/ RICHARD B. CLARK
|
|
|
|
Richard B. Clark |
|
|
|
Vice President and Controller
(On behalf of the Registrant and as Principal Accounting Officer) |
|
|
Date: June 27, 2008
45
|
|
|
MONSANTO COMPANY
|
|
THIRD QUARTER 2008 FORM 10-Q |
|
These Exhibits are numbered in accordance with the Exhibit Table of Item 601 of Regulation S-K.
|
|
|
Exhibit |
|
|
No. |
|
Description |
|
2
|
|
Sale and Purchase Agreement, dated March 31, 2008, by and between Monsanto Company and Delhi
B.V. (incorporated by reference to Exhibit 2.1 to Form 8-K, filed April 1, 2008, File No.
1-16167) |
|
|
|
3
|
|
Monsanto Company Bylaws, as amended effective June 18, 2008 (incorporated by reference to
Exhibit 3.2(i) of Form 8-K, filed June 24, 2008, File No. 1-16167). |
|
|
|
4 |
|
Monsanto Company agrees to furnish to the Securities and Exchange Commission, upon
request, copies of any long-term debt instruments that authorize an amount of securities constituting 10 percent or
less of the total assets of the company and its subsidiaries on a consolidated basis. |
|
|
|
10
|
|
Second Amendment, dated
June 18, 2008, to Monsanto Non-Employee Director Equity
Incentive Compensation Plan, as amended and restated as of
Sept. 1, 2007. |
|
|
|
11
|
|
Omitted see Note 14 of Notes to Consolidated Financial Statements Earnings Per Share. |
|
|
|
12
|
|
Computation of Ratio of Earnings to Fixed Charges. |
|
|
|
15
|
|
Omitted |
|
|
|
18
|
|
Omitted |
|
|
|
19
|
|
Omitted |
|
|
|
22
|
|
Omitted |
|
|
|
23
|
|
Omitted |
|
|
|
24
|
|
Omitted |
|
|
|
31.1
|
|
Rule 13a-14(a) Certification (pursuant to Section 302 of the Sarbanes-Oxley Act of 2002,
executed by the Chief Executive Officer). |
|
|
|
31.2
|
|
Rule 13a-14(a) Certification (pursuant to Section 302 of the Sarbanes-Oxley Act of 2002,
executed by the Chief Financial Officer). |
|
|
|
32
|
|
Rule 13(a)-14(b) Certifications (pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
executed by the Chief Executive Officer and the Chief Financial Officer). |
|
|
|
|
|
Represents management contract or compensatory plan or arrangement. |
46